55 results on '"Isabel Krsnik"'
Search Results
2. Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
- Author
-
Sunil Lakhwani, Laura Rosinol Dachs, Noemi Puig, Miguel Angel Pico Picos, Laura Medina-González, Joaquín Martínez-López, Bruno Paiva, Albert Oriol, Rafael Rios, María Jesús Blanchard, Isidro Jarque, Joan Bargay, Jose Maria Moraleda, Estrella Carrillo-Cruz, Anna Sureda, Isabel Krsnik, Esther González Garcia, Luis Felipe Casado Montero, Josep M Marti, Cristina Encinas, Felipe De Arriba, Luis Palomera, Antonia Sampol, Yolanda Gonzalez-Montes, Cristina Motllo, Javier De La Cruz, Rafael Alonso Fernández, María-Victoria Mateos, Joan Bladé Creixenti, Juan-José Lahuerta, Jesús San-Miguel, and Miguel-Teodoro Hernández
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
3. Machine Learning Model Defines Higher Risk of Venous Thromboembolism in Young Adults with Multiple Myeloma
- Author
-
Inés Martínez-Alfonzo, Diego Velasco, Pablo Mínguez Paniagua, Ignacio Mahillo-Fernández, Elham Askari, Rosa Vidal Laso, Cristina Fernández Maqueda, Alberto Velasco, Ana González-Teomiro, Maria Civeira-Marín, Elena Prieto-Pareja, Sara Martín-Herrero, José Manuel Calvo Villas, Isabel Krsnik, Joaquín Sánchez-Garcia, Miguel Angel Alvarez, María Pilar Llamas Sillero, and Juana Serrano-López
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
4. OAB-040: BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial
- Author
-
Juan José Lahuerta Palacios, Ana Jiménez Ubieto, Laura Rosiñol, Bruno Paiva, Joaquín Martinez López, María Teresa Cedena, Noemí Puig, Rafael Ríos, Albert Oriol, María Jesús Blanchard, Joan Bargay, Jesús Martín, Rafael martinez, Anna Sureda, Javier De la Rubia, Miguel teodoro Hernández, Valentín Cabañas, Isabel krsnik, Luis Palomera, Felipe Casado, Yolanda Gonzalez-Montes, Felipe de Arriba de la Fuente, María-Victoria Mateos, Jesus San-Miguel, and Joan Blade
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2022
5. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
- Author
-
Jose Enrique de la Puerta, Javier de la Rubia, Maria-Victoria Mateos, Albert Pérez-Montaña, Bruno Paiva, Gonzalo Carreño-Tarragona, Joaquin Martinez-Lopez, Albert Oriol, Felipe de Arriba, Alfonso García de Coca, Juan José Lahuerta, Jesús F. San-Miguel, María José Casanova, Noemi Puig, Enrique M. Ocio, Valentin Cabañas, Isabel Krsnik, Ramón Lecumberri, Isabel Cuenca, Esther Onecha, Mercedes Gironella, Maria Esther González, Ángel Ramírez-Payer, Beatriz Sanchez-Vega, David Gomez-Sanchez, J. Bargay, Santiago Barrio, Felipe Prosper, Daniel Alameda, Marta Lasa, Francisco Taboada, Luis Palomera, Diego Alignani, Instituto de Salud Carlos III, Fundación CRIS contra el Cáncer, Asociación Española Contra el Cáncer, International Myeloma Foundation, and Universidad de Cantabria
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Letter ,humanos ,Plasma Cells ,Research initiative ,Clonal Evolution ,03 medical and health sciences ,Disease susceptibility ,susceptibilidad a enfermedades ,0302 clinical medicine ,Cancer genomics ,Humans ,Medicine ,Genetic Predisposition to Disease ,Immunoglobulin Light-chain Amyloidosis ,mutación ,Gynecology ,business.industry ,Amyloidosis ,Disease Management ,predisposición genética a la enfermedad ,Hematology ,Translational research ,medicine.disease ,células plasmáticas ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Mutation ,Disease Susceptibility ,business ,Biomarkers ,evolución clonal - Abstract
This study was supported by the Centro de Investigación Biomédica en Red—Área de Oncología—del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369; and CB16/12/00489), Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS No. PI13/02196), Asociación Española Contra el Cáncer (GCB120981SAN and the Accelerator Award), CRIS against Cancer foundation grant 2014/0120, and the Black Swan Research Initiative of the International Myeloma Foundation.
- Published
- 2020
6. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
- Author
-
Noemí Puig, María-Teresa Contreras, Cristina Agulló, Joaquín Martínez-López, Albert Oriol, María-Jesús Blanchard, Rafael Ríos, Jesús Martín, María-Belén Iñigo, Anna Sureda, Miguel-Teodoro Hernández, Javier de la Rubia, Verónica González-Calle, Isabel Krsnik, Valentín Cabañas, Luis Palomera, José-María Moraleda, Joan Bargay, María-Teresa Cedena, Bruno Paiva, Laura Rosiñol, Joan Bladé, Jesús San Miguel, Juan-José Lahuerta, María-Victoria Mateos, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red Cáncer (España), Cancer Research UK, Fundación Científica Asociación Española Contra el Cáncer, and Fondazione Italiana per la Ricerca sul Cancro
- Subjects
Lymphoid Neoplasia ,integumentary system ,Hematopoietic Stem Cell Transplantation ,Antibodies, Monoclonal ,Hematology ,Stimulus Report ,Transplantation, Autologous ,Mass Spectrometry ,Espectrometria de masses ,hemic and lymphatic diseases ,CRITERIA ,Humans ,Monoclonal antibodies ,Immunoglobulin Light Chains ,Multiple Myeloma ,Anticossos monoclonals ,M-PROTEINS - Abstract
Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), and after induction (n = 183), autologous stem cell transplantation (n = 173), and consolidation (n = 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in >80% of cases, being most discordances due to EXENT&FLC-MS+ but IFE− cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE− patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P = .0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients’ outcome. This trial was registered at www.clinicaltrials.gov as #NCT01916252., This study was supported by grants from the Centro de Investigacion Biomédica en Red–Area de Oncología–del Instituto de Salud Carlos III CIBERONC, CB16/12/00369, CB16/12/00400, CB16/12/00233, and CB16/12/00284, Instituto de Salud Carlos III/Subdireccion General de Investigaci on Sanitaria FIS no. PI15/ 01956, PI15/02049, PI15/02062, PI18/01709, PI18/01673, and PI19/01451, the Cancer Research UK, FCAECC, and AIRC under the Accelerator Award Program (EDITOR).
- Published
- 2021
7. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
- Author
-
Ombretta Annibali, Marta Lasa, Mario Nuvolone, Leire Burgos, Pasquale Cascino, Isabel Krsnik, Sriram Ravichandran, Alice Nevone, Paolo Milani, Andrea Foli, Ashutosh D. Wechalekar, Jesús F. San-Miguel, Margherita Massa, Bruno Paiva, Ramón Lecumberri, Melania Antonietta Sesta, Giampaolo Merlini, Alberto Orfao, Pierpaolo Berti, Marco Basset, Simona Casarini, Margherita Bozzola, Giovanni Palladini, Jessica Ripepi, Noemi Puig, International Myeloma Foundation, Fondazione Cariplo, Cancer Research UK, Fundación Científica Asociación Española Contra el Cáncer, Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute, Centro de Investigación Biomédica en Red Cáncer (España), and Instituto de Salud Carlos III
- Subjects
Male ,medicine.medical_specialty ,Neoplasm, Residual ,Disease-free survival ,Gastroenterology ,lcsh:RC254-282 ,Article ,Internal medicine ,hemic and lymphatic diseases ,medicine ,AL amyloidosis ,Humans ,Immunoglobulin Light-chain Amyloidosis ,Multiple myeloma ,Aged ,business.industry ,Amyloidosis ,Organ dysfunction ,Hematology ,Minimal Residual Disease Negativity ,Middle Aged ,Translational research ,medicine.disease ,Flow Cytometry ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Minimal residual disease ,body regions ,Oncology ,Toxicity ,Disease Progression ,Female ,medicine.symptom ,business ,Complete Hematologic Response - Abstract
© The Author(s) 2021., Light chain (AL) amyloidosis is caused by a small B-cell clone producing light chains that form amyloid deposits and cause organ dysfunction. Chemotherapy aims at suppressing the production of the toxic light chain (LC) and restore organ function. However, even complete hematologic response (CR), defined as negative serum and urine immunofixation and normalized free LC ratio, does not always translate into organ response. Next-generation flow (NGF) cytometry is used to detect minimal residual disease (MRD) in multiple myeloma. We evaluated MRD by NGF in 92 AL amyloidosis patients in CR. Fifty-four percent had persistent MRD (median 0.03% abnormal plasma cells). There were no differences in baseline clinical variables in patients with or without detectable MRD. Undetectable MRD was associated with higher rates of renal (90% vs 62%, p = 0.006) and cardiac response (95% vs 75%, p = 0.023). Hematologic progression was more frequent in MRD positive (0 vs 25% at 1 year, p = 0.001). Altogether, NGF can detect MRD in approximately half the AL amyloidosis patients in CR, and persistent MRD can explain persistent organ dysfunction. Thus, this study supports testing MRD in CR patients, especially if not accompanied by organ response. In case MRD persists, further treatment could be considered, carefully balancing residual organ damage, patient frailty, and possible toxicity., This study was supported by a grant from CARIPLO “Molecular mechanisms of Ig toxicity in age-related plasma cell dyscrasias no. 2015-0591”, by a grant from the Black Swan Research Initiative from the International Myeloma Foundation “Automated multidimensional flow cytometry for high-sensitive screening and to monitor response in AL amyloidosis”, by a grant from CARIPLO “Structure–function relation of amyloid: understanding the molecular bases of protein misfolding diseases to design new treatments no. 2013-0964”, by a grant from the Amyloidosis Foundation “Investigating new therapies to treat AL amyloidosis”, and by a grant from Cancer Research UK, FCAECC and AIRC under the Accelerator Award 2017 Program “Early detection and intervention: understanding the mechanisms of transformation and hidden resistance of incurable hematological malignancies”, by a grant from CARIPLO “Harnessing the plasma cell secretory capacity against systemic light chain amyloidosis” (no. 2018-0257), by a grant from the Italian Ministry of Health “Towards effective, patient-tailored anti-plasma cell therapies in AL amyloidosis: predicting drug response and overcoming drug resistance” (GR-2018-12368387). This study has also supported the Centro de Investigación Biomédica en Red—Área de Oncología—del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369, CB16/12/00400, and CB16/12/00489) and the Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS No. PI13/02196). G.P. is supported in part by the Bart Barlogie Young Investigator Award from the International Myeloma Society (IMS). P.M. is supported in part by a fellowship grant form Collegio Ghislieri (Pavia). We acknowledge the study coordinator and data manager Anna Carnevale Baraglia.
- Published
- 2021
8. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
- Author
-
Joaquin Martinez-Lopez, Diego Alignani, Jesús Martín-Sánchez, Norma C. Gutiérrez, Juan Flores-Montero, Ibai Goicoechea, Rafael Rios, Joan Bargay, Noemi Puig, Leire Burgos, Juan José Garcés, Maria-Victoria Mateos, Juan José Lahuerta, Joan Bladé, María-Belén Vidriales, Lourdes Cordón, Maria-Jose Calasanz, Isabel Krsnik, Bruno Paiva, Miguel-Teodoro Hernández, Albert Oriol, Sara Rodriguez, Idoia Rodriguez, Maria-Teresa Cedena, Vicente Fresquet, Luis Palomera, Sarai Sarvide, J A Martinez-Climent, Amaia Vilas-Zornoza, Alberto Orfao, Javier de la Rubia, Rafael Martínez-Martínez, Ramón García-Sanz, David Lara-Astiaso, José-María Moraleda, Jesús F. San Miguel, Laura Rosiñol, Jon Celay, Josep Sarrá, María-Luisa Martín Ramos, and Daniel Alameda
- Subjects
Oncology ,Adult ,Boron Compounds ,Male ,medicine.medical_specialty ,Neoplasm, Residual ,Physics::Instrumentation and Detectors ,Clinical Trials and Observations ,Immunology ,Patient subgroups ,Glycine ,Drug resistance ,Biochemistry ,Dexamethasone ,Bortezomib ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Neoplasm ,Humans ,Progression-free survival ,Treatment resistance ,Lenalidomide ,Complete response ,Multiple myeloma ,Aged ,Chromosome Aberrations ,Lymphoid Neoplasia ,business.industry ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Flow Cytometry ,Progression-Free Survival ,body regions ,Clinical trial ,Treatment Outcome ,Drug Resistance, Neoplasm ,Female ,business ,Multiple Myeloma - Abstract
PETHEMA/GEM Cooperative Group., Patients with multiple myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete response (CR) rates, but the later have inferior progression-free survival (PFS). This questions the legitimacy of CR as a treatment endpoint and represents a biological conundrum regarding the nature of tumor reservoirs that persist after therapy in high-risk MM. We used next-generation flow (NGF) cytometry to evaluate measurable residual disease (MRD) in MM patients with standard- vs high-risk CAs (n = 300 and 90, respectively) enrolled in the PETHEMA/GEM2012MENOS65 trial, and to identify mechanisms that determine MRD resistance in both patient subgroups (n = 40). The 36-month PFS rates were higher than 90% in patients with standard- or high-risk CAs achieving undetectable MRD. Persistent MRD resulted in a median PFS of ∼3 and 2 years in patients with standard- and high-risk CAs, respectively. Further use of NGF to isolate MRD, followed by whole-exome sequencing of paired diagnostic and MRD tumor cells, revealed greater clonal selection in patients with standard-risk CAs, higher genomic instability with acquisition of new mutations in high-risk MM, and no unifying genetic event driving MRD resistance. Conversely, RNA sequencing of diagnostic and MRD tumor cells uncovered the selection of MRD clones with singular transcriptional programs and reactive oxygen species–mediated MRD resistance in high-risk MM. Our study supports undetectable MRD as a treatment endpoint for patients with MM who have high-risk CAs and proposes characterizing MRD clones to understand and overcome MRD resistance. This trial is registered at www.clinicaltrials.gov as #NCT01916252.
- Published
- 2021
9. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
- Author
-
Javier de la Rubia, Maria Victoria Mateos, David Lara-Astiaso, Amaia Vilas-Zornoza, Joaquin Martinez-Lopez, Ramón Lecumberri, Sara Rodriguez, Marco Vicari, Sonia Garate, María Teresa Cedena, Ibai Goicoechea, Assaf Weiner, Luis Palomera, María José Casanova, Sarai Sarvide, Vito Michele Fazio, Jose Enrique de la Puerta, Alfonso García de Coca, Jesús F. San Miguel, Maria Esther González, Diego Alignani, Alice Nevone, Noemi Puig, Albert Oriol, Ido Amit, Felipe de Arriba, Bruno Paiva, María D. Odero, Valentin Cabañas, Isabel Krsnik, Felipe Prosper, Enrique M. Ocio, Daniel Alameda, Marta Lasa, Elena Arriazu, Mercedes Gironella, Jorge Labrador, Albert Pérez-Montaña, Juan J. Lahuerta, and Mario Nuvolone
- Subjects
Adult ,Plasma Cells ,Immunology ,Biology ,Plasma cell ,Immunoglobulin light chain ,Biochemistry ,CD19 ,CME article ,Tumor Cells, Cultured ,medicine ,Humans ,Immunoglobulin Light-chain Amyloidosis ,Free Research Articles ,Multiple myeloma ,Lymphoid Neoplasia ,Amyloidosis ,Cell Biology ,Hematology ,medicine.disease ,humanities ,medicine.anatomical_structure ,Monoclonal ,biology.protein ,Cancer research ,Brief Reports ,Bone marrow ,Multiple Myeloma ,Transcriptome ,Monoclonal gammopathy of undetermined significance - Abstract
Although light-chain amyloidosis (AL) and multiple myeloma (MM) are characterized by tumor plasma cell (PC) expansion in bone marrow (BM), their clinical presentation differs. Previous attempts to identify unique pathogenic mechanisms behind such differences were unsuccessful, and no studies have investigated the differentiation stage of tumor PCs in patients with AL and MM. We sought to define a transcriptional atlas of normal PC development in secondary lymphoid organs (SLOs), peripheral blood (PB), and BM for comparison with the transcriptional programs (TPs) of tumor PCs in AL, MM, and monoclonal gammopathy of undetermined significance (MGUS). Based on bulk and single-cell RNA sequencing, we observed 13 TPs during transition of normal PCs throughout SLOs, PB, and BM. We further noted the following: CD39 outperforms CD19 to discriminate newborn from long-lived BM-PCs; tumor PCs expressed the most advantageous TPs of normal PC differentiation; AL shares greater similarity to SLO-PCs whereas MM is transcriptionally closer to PB-PCs and newborn BM-PCs; patients with AL and MM enriched in immature TPs had inferior survival; and protein N-linked glycosylation–related TPs are upregulated in AL. Collectively, we provide a novel resource to understand normal PC development and the transcriptional reorganization of AL and other monoclonal gammopathies.
- Published
- 2021
10. Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial
- Author
-
Jesús Martín, Javier de la Rubia, Maria-Victoria Mateos, Laura Rosiñol, Cristina Agullo, Joaquin Martinez-Lopez, Albert Oriol, Juan José Lahuerta, Ramón García-Sanz, Miguel T. Hernandez, Belén Iñigo, Isabel Krsnik, Rafael Rios, Bruno Paiva, Noemi Puig, Teresa Contreras Sanfeliciano, Joan Blade Creixenti, María Jesús Blanchard, Luis Palomera, José M. Moraleda, María Teresa Cedena, Anna Sureda, Jesús F. San-Miguel, and Joan Bargay
- Subjects
Clinical trial ,Treatment response ,Chromatography ,medicine.diagnostic_test ,Chemistry ,Immunology ,medicine ,Cell Biology ,Hematology ,Mass spectrometry ,Biochemistry ,Flow cytometry - Abstract
Introduction : In patients (pts) with multiple myeloma (MM), next generation flow cytometry (NGF) and next generation sequencing have shown an increased capacity to identify the presence of disease and to anticipate patient's prognosis as compared to serum protein immunofixation (IFE). However, both methods rely on bone marrow (BM) samples and it is important to explore alternative techniques applicable in more accessible samples such as peripheral blood. Patients and Methods: Newly diagnosed MM pts enrolled in the PETHEMA/GEM2012MENOS65 trial received six cycles of induction with bortezomib, lenalidomide and dexamethasone (VRD), intensification with high-dose therapy (melphalan or busulfan and melphalan) followed by autologous stem cell transplantation and consolidation with two more cycles of VRD. At the end of the treatment (post-consolidation), the M-protein (MP) was analyzed in serum by conventional IFE and by EXENT Quantitative Immunoprecipitation Mass Spectrometry using IgG/A/M, κ, λ, free κ and free λ isotypic beads; negative samples by EXENT were re-analyzed by liquid chromatography mass spectrometry (LC-MS). The presence of clonal plasma cells in BM samples was investigated by NGF following the Euroflow guidelines (sensitivity≥10 -5). Samples from the first 164 pts enrolled in the trial were analyzed in this study. Results : After consolidation, persistent disease was detected in 42 (26%) pts by IFE, in 56 (34%) by EXENT and in 72 (44%) by NGF. Surprisingly, the presence or absence of disease by IFE did not discriminate pts with different progression-free survival (PFS), but both EXENT and NGF segregated two cohorts with a significantly different PFS (p=0.0016 and p Analyzing the results obtained with EXENT and NGF, we found that 76% were concordant (44 EXENT +/NGF +, 80 EXENT -/NGF -) and 24% discordant (28 EXENT -/NGF + and 12 EXENT +/NGF -). When we compared pts´ PFS according the combined results of both methods (fig 1D), we learnt that the 3 comparisons reaching statistical significance were EXENT +/NGF + vs EXENT -/NGF - (p Samples deemed negative by EXENT were re-analyzed with LC-MS. In 63 of them (58%) the MP was identified using LC-MS and therefore a total of 119 samples (73%) were considered positive with EXENT&LC-MS. We first confirmed that EXENT&LC-MS segregated two cohorts with different PFS (fig 1B, p=0.0193) Then, as earlier, we analyzed the results obtained with EXENT&LC-MS and NGF, finding that 65% were concordant (67 EXENT&LC-MS +/NGF +, 40 EXENT&LC-MS -/NGF -) and 35% discordant (5 EXENT&LC-MS -/NGF + and 52 EXENT&LC +/NGF -). Again, we compared pts´ PFS according the combined results of both methods (fig 1E) learning now that only the comparisons EXENT&LC-MS +/NGF + vs EXENT&LC-MS -/NGF - (p=0.0006) and EXENT&LC-MS +/NGF + vsEXENT&LC-MS +/NGF - (p=0.0006) reached statistical significance. With these results, the NPV of EXENT&LC-MS was 89% overall (100% in MRD levels ≥10 -4 p Finally, we observed that whereas among pts deemed EXENT +, NGF identified 2 cohorts with different PFS (a NGF -group of 12 pts displaying a longer PFS as compared with those NGF +; median PFS: 4 years vs not reached, p=0.039) among EXENT&LC-MS - cases (n=45) NGF was not able to show any added clinical value. Conclusions : The use of IFE post-consolidation in pts with MM, as opposed to EXENT and NGF, did not identify pts with different PFS. When referred to NGF, EXENT provided a similar clinical value and displayed a very high NPV, increased further with the addition of LC-MS; this could be utilised to avoid the performance of a BM aspiration after treatment in pts with undetectable disease. Regarding EXENT + and/or LC-MS + cases future quantitative and sequential studies could reveal whether are due to the long half-lives of the MP or represent quiescent low-level disease. Figure 1 Figure 1. Disclosures Puig: Amgen, Celgene, Janssen, Takeda and The Binding Site: Honoraria; Amgen, Celgene, Janssen, Takeda: Consultancy; Celgene: Speakers Bureau; Celgene, Janssen, Amgen, Takeda: Research Funding. Paiva: Bristol-Myers Squibb-Celgene, Janssen, and Sanofi: Consultancy; Adaptive, Amgen, Bristol-Myers Squibb-Celgene, Janssen, Kite Pharma, Sanofi and Takeda: Honoraria; Celgene, EngMab, Roche, Sanofi, Takeda: Research Funding. Cedena: Janssen, Celgene and Abbvie: Honoraria. Rosinol: Janssen, Celgene, Amgen and Takeda: Honoraria. Martínez-López: Roche, Novartis, Incyte, Astellas, BMS: Research Funding; Janssen, BMS, Novartis, Incyte, Roche, GSK, Pfizer: Consultancy. Oriol: Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Sureda: Bluebird: Membership on an entity's Board of Directors or advisory committees; Kite, a Gilead Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding, Speakers Bureau; GSK: Consultancy, Honoraria, Speakers Bureau; Roche: Other: Support for attending meetings and/or travel; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Mundipharma: Consultancy; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Moraleda: Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Gilead: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Novartis: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Sandoz: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Other: Educational Grants, Research Funding; ROCHE: Consultancy, Honoraria, Other: Educational Grants, Research Funding; MSD: Other: Educational Grants, Research Funding; Sanofi: Other: Educational Grants, Research Funding; Pfizer: Other: Educational Grants, Research Funding; NovoNordisk: Other: Educational Grants, Research Funding; Janssen: Other: Educational Grants, Research Funding; Celgene: Other: Educational Grants, Research Funding; Amgen: Other: Educational Grants, Research Funding. Bladé Creixenti: Janssen, Celgene, Takeda, Amgen and Oncopeptides: Honoraria. San-Miguel: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, and Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees. Mateos: Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird bio: Honoraria; GSK: Honoraria; Oncopeptides: Honoraria.
- Published
- 2021
11. Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience
- Author
-
Ana Morales, Isabel Krsnik, Carmen Jiménez-Montes, Carmen Martínez-Chamorro, María Jesús Blanchard, Cristina Muñoz-Linares, Adrian Alegre, Alberto Velasco, Rebeca Iglesias, Elham Askari, Concha Alaez, Arancha Alonso, Clara Cuellar, Elena Prieto, Ana Jiménez-Ubieto, Eugenio Gimenez Mesa, Gonzalo Benzo Callejo, Joaquin Martinez-Lopez, Beatriz Aguado, Laura Llorente, and Rafael Alonso Fernández
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Compassionate Use ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Internal medicine ,Relapsed refractory ,Medicine ,business ,Multiple myeloma - Abstract
Background: Heavily pretreated relapsed and refractory multiple myeloma (RR MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short (Richardson et al. 2007). Belantamab Mafodotin (BM), a novel anti-BCMA antibody conjugated to microtubule-disrupting agent monomethyl auristatin F, showed single-agent activity in the phase 1 DREAMM-1 and phase 2 DREAMM-2 studies in heavily pre-treated patients with RRMM (Lonial et al, 2019 & 2021). We aim to assess efficacy and safety of BM treatment administered via the expanded access compassionate care program for triple class MMRR patients in the region of Madrid (Spain). Methods: An observational, retrospective and multicenter study has been performed including all patients who received at least one dose of BM under the expanded access program in the region of Madrid (Spain) from Nov 2019 to Jun 2021. Hematology centers provided data from the medical records and entered them in a case report form distributed to the sites. Primary endpoint was overall response rate (ORR). Secondary endpoints were progression free survival (PFS), overall survival (OS) and the incidence of treatment emergent adverse events (TEAEs), with a major focus on ocular and hematologic toxicity. Results: A total of 33 patients (pts), from 14 different centers, were included from February 2020 till May 2021. Median age was 70 (46-79) years. 55% of the pts were women. Median time from diagnosis was 71 (10-858) months. 30.3% were high-risk cytogenetic features. Median of prior therapy lines was 5 (3-8) and at least 88% of the pts were triple class refractory. The median number of BM doses per patient was 3 (1-16) and the median follow-up was 11 months (95%CI 6.34-15.66). ORR was 42.2%, and 18.2% achieved ≥VGPR. Median PFS was 3 months (95%CI 0.92-5.08). Median PFS for patients who achieved ≥PR was 11 months (HR 0,26; 95% CI 0,10-0,68). No significant differences were found in PFS according to age, cytogenetic risk and prior therapy lines. OS was 424 days (95% CI 107-740). The incidence of non-hematological TEAEs was 57.6% and the most common of which was ocular toxicity (45.5%). The incidence of ≥G3 non-hematological TEAEs was 30.3%. 51.5% of the pts were diagnosed of keratopathy and 21.2% was ≥G3. 30.3% of the pts showed a reduced visual acuity, but this event was resolved in 92.9% of the pts. The most common symptoms were blurry vision (30.3%, n=10) and dry eye (24.2%, n=8). The incidence of ≥G3 hematological TEAEs was 18.2% and thrombocytopenia was the most frequent (21.2%). Dose reductions of BM were required in 30.3% of the pts and delayed in 36.4% due to TEAEs. Main causes for treatment discontinuation (81%, n=27) were disease progression (54.5%, n=18), toxicity (15.2%, n=5), death (6.1%, n=3) and due to patient's decision (3%, n=1). Conclusion: Compassionate use of BM in heavily pretreated RR MM pts showed a relevant anti-myeloma activity with a manageable safety profile.These results are similar to those observed in the DREAMM-1 and DREAMM-2 clinical trials. Disclosures No relevant conflicts of interest to declare.
- Published
- 2021
12. Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies
- Author
-
Leire Burgos, Luis Esteban Tamariz-Amador, Noemí Puig, María Teresa Cedena, Tomas Jelinek, Sarah K Johnson, Paolo Milani, Lourdes Cordon, José J Pérez, Marta Lasa, Rosalinda Termini, Albert Oriol, Miguel-Teodoro Hernández, Luis Palomera, Rafael Martinez Martinez, Javier de la Rubia, Felipe De Arriba, Rafael Rios, Maria Esther González, Mercedes Gironella, Valentin Cabañas, Maria Casanova, Isabel Krsnik, Albert Pérez, Veronica Gonzalez De La Calle, Paula Rodríguez-Otero, Vladimir Maisnar, Roman Hajek, Frits van Rhee, Victor H Jimenez-Zepeda, Giovanni Palladini, Alberto Orfao, Laura Rosinol, Joan Bladé Creixenti, Joaquín Martínez-López, Juan-José Lahuerta, Maria-Victoria Mateos, Jesús F. San-Miguel, and Bruno Paiva
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Immunology ,Monoclonal ,Medicine ,Clinical significance ,Cell Biology ,Hematology ,business ,Biochemistry ,Phenotype - Abstract
Background: Within the spectrum of monoclonal gammopathies, there are various subgroups with unique biological and clinical profiles. Namely, the presence of multiple myeloma (MM) and light-chain amyloidosis (AL) pts with MGUS-like phenotype has been hypothesized, but the criteria to identify this subgroup are poorly defined and lack clinical validation. Aim: Develop an algorithm based on a large flow cytometry dataset across the spectrum of monoclonal gammopathies, for automated identification of MM and AL pts with MGUS-like phenotype. Methods: This study included 5,114 pts with monoclonal gammopathies and available flow cytometry data on the frequency of bone marrow (BM) plasma cells (PC) and the percentages of normal and clonal PC within the BM PC compartment, at diagnosis. An algorithm to classify pts with MGUS-like phenotype was developed based on these three parameters, obtained from 548 MGUS, 393 smoldering MM (SMM) and 2,011 MM pts. Newly diagnosed MM pts were homogeneously treated according to the GEM2000 (n = 486), GEM2005MENOS65 (n = 330), GEM2005MAS65 (n = 239), GEM2010MAS65 (n = 230), GEM2012MENOS65 (n = 450) and CLARIDEX (n = 276) protocols. The prognostic value of the MGUS-like phenotype was validated in 96 SMM pts studied in Arkansas and 1,859 MM pts treated outside clinical trials in Czech Republic. The clinical significance of the algorithm was investigated in two independent series of Spanish (n = 102) and Italian (n = 105) AL pts. Results: The frequency of BM PC and of normal and clonal PC within the BM PC compartment were used to plot MGUS, SMM and MM pts in a principal component analysis (PCA). Lines defining 1.5 standard deviations of MGUS and MM pts were used as reference to classify each of the 5,114 cases. Once plotted against the dataset, individual pts were classified as MGUS-, intermediate- or MM-like, if their location in the PCA fell inside the MGUS, the overlapping or the MM reference lines, respectively. In the training SMM series, patient classification into MGUS-, intermediate- and MM-like phenotype resulted in significantly different rates of disease progression (0%, 54% and 66% at 5y, respectively; P < .001). These results were validated in the Arkansas series (8%, 27% and 71% at 5y, respectively; P < .001). Only 5% of SMM pts with high-risk disease according to Mayo or PETHEMA criteria had an MGUS-like phenotype, and these had virtually no risk of progression at 5y. In the training MM series, pts with MGUS-like phenotype showed significantly longer progression free (PFS) and overall survival (OS) vs the remaining pts. Median PFS was 10y vs 3y (hazard ratio [HR]: 0.46, P < .001) and median OS was not reached (NR) vs 6.5y (HR: 0.48, P < .001), respectively. These results were validated in the Czech Republic series with significant differences in PFS (HR: 0.45, P < .001) and OS (HR: 0.38, P < .001) between MGUS-like vs other MM pts. MGUS-like classification in the training MM series retained independent prognostic value in multivariate analyses of PFS (HR: 0.48, P < .001) and OS (HR: 0.54, P = .033), together with ISS, LDH, cytogenetics, induction regimen, transplant-eligibility and complete remission (CR). MGUS-like pts showed similar PFS (P = .932) and OS (P = .285) regardless of having standard vs high risk cytogenetics. Notably, MGUS-like transplant-eligible MM pts treated with proteasome inhibitors, immunomodulatory drugs and corticoids during induction showed PFS and OS rates at 5y of 86% and 96%, respectively. Differences in PFS among MGUS-like MM pts achieving ≥CR vs Classification of AL pts into the MGUS-, intermediate- and MM-like phenotype resulted in significantly different PFS in the Spanish (median of 28, 20 and 1 months, respectively; P = .001) and Italian (median 32, 11 and 3 months, respectively; P < .001) cohorts. Conclusions: We developed an algorithm that can be readily installed in clinical flow cytometry software, and requires three parameters that are routinely assessed at screening. Patient' automated classification using the algorithm was validated in large series across the spectrum of monoclonal gammopathies. Because pts with MGUS-like phenotype have a distinct clinical behavior, their identification could become part of the diagnostic workup in SMM, MM and AL. Disclosures Cedena: Janssen, Celgene and Abbvie: Honoraria. Milani: Celgene: Other: Travel support; Janssen-Cilag: Honoraria. Cordon: Cytognos SL: Research Funding. Oriol: Takeda: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Janssen: Consultancy. de la Rubia: Amgen, Bristol Myers Squibb,: Honoraria, Speakers Bureau; Celgene, Takeda, Janssen, Sanofi: Honoraria; Ablynx/Sanofi: Consultancy; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; AbbVie: Consultancy; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel Accommodations; GSK: Consultancy; Takeda: Consultancy; Sanofi: Membership on an entity's Board of Directors or advisory committees. De Arriba: Amgen: Consultancy, Honoraria; Glaxo Smith Kline: Consultancy, Honoraria; BMS-Celgene: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau. Cabañas: Janssen: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Sanofi: Honoraria. Gonzalez De La Calle: Celgene-BMS, Janssen, Amgen: Honoraria. Rodríguez-Otero: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and other expenses. Hajek: Pharma MAR: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding. Jimenez-Zepeda: BMS, Amgen, Takeda, Janssen: Honoraria. Palladini: Janssen Global Services: Honoraria, Other: advisory board fees; Pfizer: Honoraria; Siemens: Honoraria. Rosinol: Janssen, Celgene, Amgen and Takeda: Honoraria. Bladé Creixenti: Janssen, Celgene, Takeda, Amgen and Oncopeptides: Honoraria. Martínez-López: Janssen, BMS, Novartis, Incyte, Roche, GSK, Pfizer: Consultancy; Roche, Novartis, Incyte, Astellas, BMS: Research Funding. Mateos: Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird bio: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Honoraria; Oncopeptides: Honoraria. San-Miguel: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, Takeda: Consultancy, Other: Advisory board. Paiva: Bristol-Myers Squibb-Celgene, Janssen, and Sanofi: Consultancy; Adaptive, Amgen, Bristol-Myers Squibb-Celgene, Janssen, Kite Pharma, Sanofi and Takeda: Honoraria; Celgene, EngMab, Roche, Sanofi, Takeda: Research Funding.
- Published
- 2021
13. Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
- Author
-
Maria-Victoria Mateos, Esther González Garcia, Yolanda Gonzalez-Montes, Antonia Sampol, Elena Cabezudo, Rafael Ríos Tamayo, Joan Blade Creixenti, María Jesús Blanchard, Jesús F. San-Miguel, Estrella Carrillo-Cruz, Felipe Casado, Joan Bargay, Anna Sureda, José M. Moraleda, Josep Martí, Luis Palomera, Laura Rosiñol, Isabel Krsnik, Joaquin Martinez-Lopez, Cristina Encinas, Felipe de Arriba, Miguel-Teodoro Hernández, Albert Oriol, Isidro Jarque, and Juan José Lahuerta
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Cell Biology ,Hematology ,Newly diagnosed ,medicine.disease ,Biochemistry ,Ixazomib ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,In patient ,Stem cell ,business ,Dexamethasone ,Multiple myeloma ,medicine.drug ,Lenalidomide - Abstract
Background: The Spanish Myeloma Group (GEM) demonstrated that post-transplant maintenance with thalidomide plus bortezomib was superior to thalidomide alone, although this combination was associated with a high rate of peripheral neuropathy. Lenalidomide is currently the standard postransplant maintenance treatment, and its association with ixazomib, an oral proteasome inhibitor that does not cause peripheral neuropathy, could be of interest. Aim: To assess the potential benefit of postransplant maintenance therapy with Ixazomib /lenalidomide/dexamethasone (IRd) over lenalidomide/dexamethasone (Rd). Patients: Patients who where at least with stable disease after the GEM2012menos65 trial that included VRD-GEM induction, autologous hematopoietic stem cell transplantation conditioned with either melphalan-200 or intravenous busulfan together with melphalan-140 and consolidation with VRD-GEM were randomized to receive maintenance treatment with IRd versus Rd. Each cycle lasted 28 days. Rd arm consisted of lenalidomide 15 mg/d on days 1-21 and 20mg of dexamethasone administered orally on days 1-4 and 9-12. In IRd arm ixazomib 4 mg/day on days 1, 8 and 15 of the cycle was added. At two years, patients with negative MRD discontinued maintenance treatment. Patients with positive MRD continued with Rd for 3 additional years. In this case, 20 mg of dexamethasone was only administered on days 1-4 of the cycle. From November 24, 2014 to May 18, 2017, 161 patients were allocated to Rd arm and 171 to IRd arm. Patient characteristics at screening and prognostic factors such as ISS, cytogenetics and plasmacytomas, as well as response status, were similarly distributed in the two arms. Overall, 22% of the patients had high-risk cytogenetics [t(4;14), t(14;16) and/or 17p deletion]. MRD was analyzed by using next-generation flow at a sensitivity level of 3x10 -6. Results: After a median follow-up of 56 months, there was no difference in PFS between the two maintenance arms (median not reached, PFS at 5 years: 62% vs. 63% with IRd and Rd, respectively, p=0.785) (figure 1). In the overall series, there were no significant differences in PFS or OS among patients with standard (SR) or high-risk (HR) cytogenetics. Median PFS had not been reached in patients with SR in both arms (PFS at 5 years: 66% with IRD vs. 62% with Rd, p=0.633). In patients with HR the median PFS was 62 months with IRd vs. not reached with Rd (p=0.636). No significant differences across subgroups (ISS, conditioning, cytogenetics or MRD) were observed between IRd and Rd. Negative MRD at screening overcomes the bad prognosis of cytogenetics (PFS at 5 years 78% for SR and 80% for HR; OS at 5 years was 90% for both, SR and HR). Patients with SR who had negative MRD at screening had a significantly longer PFS (PFS at 5 years 78% vs. 50%, p Conclusions: Maintenance therapy with lenalidomide and dexamethasone in patients homogeneously treated with VRD-GEM induction, ASCT and VRD-GEM consolidation resulted in a long PFS of 63% at 5 years from the start of maintenance. The addition of ixazomib did not result in a PFS benefit. This could be partially explained by the higher toxicity leading to dose reductions or discontinuation of ixazomib in the IRd arm. Figure 1 Figure 1. Disclosures Rosinol: Janssen, Celgene, Amgen and Takeda: Honoraria. Oriol: Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Jarque: AbbVie: Consultancy, Speakers Bureau; Alexion: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Apellis: Consultancy; AstraZeneca: Consultancy, Speakers Bureau; Beigene: Consultancy; CellTrion: Consultancy; Eusa: Consultancy; Gilead: Consultancy, Speakers Bureau; Grifols: Consultancy; Incyte: Consultancy; Janssen: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Servier: Speakers Bureau; Shionogi: Consultancy; Sobi: Consultancy; Takeda: Consultancy, Speakers Bureau. Moraleda: Pfizer: Other: Educational Grants, Research Funding; Sanofi: Other: Educational Grants, Research Funding; MSD: Other: Educational Grants, Research Funding; ROCHE: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Takeda: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Sandoz: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Gilead: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Educational Grants, Research Funding; NovoNordisk: Other: Educational Grants, Research Funding; Janssen: Other: Educational Grants, Research Funding; Celgene: Other: Educational Grants, Research Funding; Amgen: Other: Educational Grants, Research Funding. Sureda: Mundipharma: Consultancy; Bluebird: Membership on an entity's Board of Directors or advisory committees; Roche: Other: Support for attending meetings and/or travel; GSK: Consultancy, Honoraria, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite, a Gilead Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding, Speakers Bureau. Martínez-López: Roche, Novartis, Incyte, Astellas, BMS: Research Funding; Janssen, BMS, Novartis, Incyte, Roche, GSK, Pfizer: Consultancy. De Arriba: BMS-Celgene: Consultancy, Honoraria, Speakers Bureau; Glaxo Smith Kline: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Speakers Bureau. Mateos: Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird bio: Honoraria; GSK: Honoraria; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria; Oncopeptides: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. San-Miguel: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, and Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees. Lahuerta: Celgene: Other: Travel accomodations and expenses; Celgene, Takeda, Amgen, Janssen and Sanofi: Consultancy. Bladé Creixenti: Janssen, Celgene, Takeda, Amgen and Oncopeptides: Honoraria.
- Published
- 2021
14. Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry
- Author
-
Lourdes Escoda, Manuel Barrios, Isabel Krsnik, Olga Salamero, Fernando Ramos, Susana Vives, Jalanta Oleksiuk, Manuel Pérez-Encinas, Félix Manso, David Martínez-Cuadrón, José González-Campos, Marta Sobas, Cristina Gil, Pau Montesinos, Andrés Novo, Celina Benavente, Josefina Serrano, Javier de la Serna, Salut Brunet, Miguel A. Sanz, Jordi Esteve, Mari-Luz Amigo, Pethema, Raimundo García-Boyero, J. Arias, Palg Groups, European Commission, and Centro de Investigación Biomédica en Red Cáncer (España)
- Subjects
Acute promyelocytic leukemia ,Male ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Population ,Tretinoin ,AIDA Regimen ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Leukemia, Promyelocytic, Acute ,Induction Death ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Elderly APL ,APL prognostic factors ,Registries ,education ,neoplasms ,Aged ,Aged, 80 and over ,education.field_of_study ,business.industry ,Remission Induction ,Complete remission ,Hematology ,medicine.disease ,Induction mortality in APL ,Survival Rate ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,APL real life outcomes ,Treatment strategy ,Female ,Neoplasm Recurrence, Local ,business ,Idarubicin ,030215 immunology ,Follow-Up Studies - Abstract
PETHEMA And PALG Groups., Acute promyelocytic leukemia is infrequent among patients aged ≥75 years old, a population that is rarely eligible for clinical protocols. This study aims to analyze the treatment strategies and clinical outcomes of very old APL patients reported to the international PETHEMA registry. Between 1997 and 2017, among 2501 APL cases registered 120 were ≥75 years old. Treatment approaches were: AIDA regimen, 79 patients; ATRA alone, 23; 16, supportive care (SC) and 2, other strategies. Patients treated with AIDA were younger, had better ECOG and lower leukocytes. Complete remission (CR) was achieved in 65% of AIDA-group vs. 45% in the ATRA-group, being infections followed by bleeding the most frequent causes of induction death. Patients in CR after AIDA showed 3-year DFS of 73%. Our real-life series of very old APL patients provides a reference basis for future treatment strategies aiming to improve clinical outcomes in this challenging population., This work was partially financed with FEDER Funds (CIBERONC (CB16/12/00284)).
- Published
- 2019
15. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
- Author
-
Alfonso García de Coca, Alberto Orfao, Albert Pérez-Montaña, Mercedes Gironella, María José Casanova, Noemi Puig, Valentin Cabañas, Isabel Krsnik, Quentin Lecrevisse, Jose-Enrique de la Puerta, Bruno Paiva, Juana Merino, Felipe Prosper, Enrique M. Ocio, Juan José Lahuerta, Cristina Moreno, Javier Verde, Felipe de Arriba, Jesús F. San Miguel, Maria-Teresa Cedena, Ramón Lecumberri, Dolores Gómez Toboso, Maria Victoria Mateos, Leire Burgos, Jorge Labrador, Luis Palomera, María Belén Vidriales, Joaquin Martinez-Lopez, José de Jesús Pérez, Javier de la Rubia, Maria-Esther Gonzalez, Marta Lasa, Albert Oriol, Instituto de Salud Carlos III, Asociación Española Contra el Cáncer, International Myeloma Foundation, and European Research Council
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,Identification ,Plasma-cells ,Myeloma ,Translocation (11/14) ,0302 clinical medicine ,Immunophenotyping ,Bone Marrow ,Mass Screening ,Immunoglobulin Light-chain Amyloidosis ,Multiple myeloma ,Aged, 80 and over ,Amyloidosis ,Diagnosed AL amyloidosis ,Hematology ,Middle Aged ,Flow Cytometry ,Immunoglobulin Isotypes ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,CD43 expression ,Female ,Adult ,medicine.medical_specialty ,Risk Assessment ,Differential-diagnosis ,Clonal Evolution ,Multiple-myeloma ,03 medical and health sciences ,Internal medicine ,medicine ,AL amyloidosis ,Humans ,Adverse prognostic-factor ,Mass screening ,Aged ,Neoplasm Staging ,Haematological cancer ,business.industry ,Minimal residual disease ,Translational research ,medicine.disease ,Staging system ,030104 developmental biology ,Bone marrow ,Differential diagnosis ,business ,Biomarkers - Abstract
Early diagnosis and risk stratification are key to improve outcomes in light-chain (AL) amyloidosis. Here we used multidimensional-flow-cytometry (MFC) to characterize bone marrow (BM) plasma cells (PCs) from a series of 166 patients including newly-diagnosed AL amyloidosis (N = 94), MGUS (N = 20) and multiple myeloma (MM, N = 52) vs. healthy adults (N = 30). MFC detected clonality in virtually all AL amyloidosis (99%) patients. Furthermore, we developed an automated risk-stratification system based on BMPCs features, with independent prognostic impact on progression-free and overall survival of AL amyloidosis patients (hazard ratio: ≥ 2.9;P ≤.03). Simultaneous assessment of the clonal PCs immunophenotypic protein expression profile and the BM cellular composition, mapped AL amyloidosis in the crossroad between MGUS and MM; however, lack of homogenously-positive CD56 expression, reduction of B-cell precursors and a predominantly-clonal PC compartment in the absence of an MM-like tumor PC expansion, emerged as hallmarks of AL amyloidosis (ROC-AUC = 0.74;P, This study was supported by the Centro de Investigación Biomédica en Red – Área de Oncología—del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369, CB16/12/00400 and CB16/12/00489), Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS No. PI13/02196), Asociación Española Contra el Cáncer (GCB120981SAN and Accelerator Award), the Black Swan Research Initiative of the International Myeloma Foundation, and the European Research Council (ERC) 2015 Starting Grant (MYELOMANEXT).
- Published
- 2019
16. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
- Author
-
Isabel Krsnik, Jesús F. San Miguel, Laura Rosiñol, María Jesús Blanchard, J. Bargay, Miguel T. Hernandez, Bruno Paiva, Maria-Victoria Mateos, Felipe de Arriba, Yolanda Gonzalez-Montes, Lucia Lopez-Anglada, Joan Bladé, Luis Palomera, A.-P. González, José M. Moraleda, Josep Martí, Mercedes Gironella, Rafael Rios, Anna Sureda, Maria Esther González, Albert Oriol, Luis Felipe Casado, Isidro Jarque, Juan José Lahuerta, Rafael Martínez-Martínez, and Jose M Arguiñano
- Subjects
Melphalan ,Oncology ,Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,Immunology ,Population ,Neutropenia ,Biochemistry ,Transplantation, Autologous ,Dexamethasone ,Bortezomib ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,education ,Lenalidomide ,Multiple myeloma ,Aged ,education.field_of_study ,Lymphoid Neoplasia ,business.industry ,Hematopoietic Stem Cell Transplantation ,Cell Biology ,Hematology ,Induction Chemotherapy ,Middle Aged ,medicine.disease ,Neoadjuvant Therapy ,Transplantation ,Chemotherapy, Adjuvant ,Female ,business ,Multiple Myeloma ,medicine.drug - Abstract
Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012 study, in 458 patients aged ≤65 years with NDMM, is evaluating bortezomib (subcutaneous) + lenalidomide + dexamethasone (VRD) for 6 cycles followed by autologous stem cell transplant (ASCT) conditioned with IV busulfan + melphalan vs melphalan and posttransplant consolidation with 2 cycles of VRD. We present grouped response analysis of induction, transplant, and consolidation. Responses deepened over time; in patients who initiated cycle 6 of induction (n = 426), the rates of a very good partial response or better were 55.6% by cycle 3, 63.8% by cycle 4, 68.3% by cycle 5, and 70.4% after induction. The complete response rate of 33.4% after induction in the intent-to-treat (ITT) population, which was similar in the 92 patients with high-risk cytogenetics (34.8%), also deepened with further treatment (44.1% after ASCT and 50.2% after consolidation). Rates of undetectable minimal residual disease (median 3 × 10(−6) sensitivity) in the ITT population also increased from induction (28.8%) to transplant (42.1%) and consolidation (45.2%). The most common grade ≥3 treatment-emergent adverse events during induction were neutropenia (12.9%) and infection (9.2%). Grade ≥2 peripheral neuropathy (grouped term) during induction was 17.0%, with a low frequency of grade 3 (3.7%) and grade 4 (0.2%) events. VRD is an effective and well-tolerated regimen for induction in NDMM with deepening response throughout induction and over the course of treatment. This trial was registered at www.clinicaltrials.gov as #NCT01916252 and EudraCT as #2012-005683-10.
- Published
- 2019
17. Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics
- Author
-
Javier de la Rubia, Ramón García-Sanz, David Lara-Astiaso, María-Belén Vidriales, Alberto Orfao, Josep Sarrá, Joaquin Martinez-Lopez, Luis Palomera, Jesús F. San-Miguel, Sarai Sarvide, Rafael Rios, Diego Alignani, Maria-Victoria Mateos, Bruno Paiva, Idoia Rodriguez, Laura Rosiñol, Isabel Krsnik, Joan Bargay, María Teresa Cedena, Joan Bladé, Leire Burgos, Miguel T. Hernandez, José M. Moraleda, Juan Flores-Montero, Ibai Goicoechea, Amaia Vilas-Zornoza, Jesús Martín, Maria Luisa Martin-Ramos, Noemi Puig, Lourdes Cordón, Albert Oriol, María José Calasanz, Norma C. Gutiérrez, Rafael Martínez, and Juan José Lahuerta
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Complete remission ,Tumor cells ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Minimal residual disease ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,Standard Risk ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Clinical significance ,Progression-free survival ,business ,health care economics and organizations ,Multiple myeloma ,030215 immunology - Abstract
Background: Despite significant improvements in the treatment of MM, the outcome of patients with HR cytogenetics remains poor despite similar complete remission (CR) rates as compared to SR cases. Relapses among patients in CR are attributed to the persistence of MRD, but knowledge about the impact of MRD in patients with SR and HR cytogenetics, treated with modern therapies and monitored with next-generation techniques, is limited. Similarly, there is virtually no data about in vivo mechanisms of resistance in SR and HR MM; however, since MRD represents those very few cells that are resistant to treatment, it could be hypothesized that profiling MRD cells may shed light into the mechanisms of resistance in both SR and HR patients. Aim: To determine the clinical impact of MRD in MM patients with SR vs HR cytogenetics, and to identify transcriptional mechanisms determining MRD resistance by investigating the transcriptome of MRD cells in both patient subgroups. Methods: This study was conducted in a series of 390 patients enrolled in the PETHEMA/GEM2012 trial (6 induction cycles with VRD followed by ASCT and 2 courses of consolidation with VRD). FISH was analyzed on CD138 purified PCs at diagnosis. MRD was predefined to be prospectively assessed following induction, transplant and consolidation, using next-generation flow (NGF) according to EuroFlow. In 40 patients [28 with SR and 12 with HR cytogenetics: i.e., t(4;14), t(14;16) and/or del(17p)], diagnostic and MRD tumor cells persisting after VRD-induction were isolated by FACS according to patient-specific aberrant phenotypes. Due to the small number of sorted MRD cells (median of 25,600) we used a 3' end RNAseq method optimized for generating libraries from low-input starting material (MARSeq). Differential expression analyses were performed with DESeq2 R package. Results: At the latest time-point in which MRD was assessed, MRD-positive rates progressively increased (p =.006) from SR patients (148/300, 49%) to cases with t(4;14) (24/42, 57%) and del(17p) (29/38, 76%). Furthermore, MRD levels were significantly superior in patients with del(17p) compared to SR FISH (0.02% vs 0.006%, p =.009), while MRD levels in patients with t(4;14) (0.004%) were similar to those in SR MM. Only 10 patients had a t(14;16) and 4 were MRD-positive. Among patients achieving MRD-negativity (.05). Conversely, 3-year PFS rates for MRD-positive patients decreased from those having SR FISH to those with t(4;14) and del(17p) (59%, 46% and 24%, respectively), with statistically significant differences between the first and the latest subgroups (p Since clearance of MRD notably lowered the risk of relapse and persistence of MRD significantly shortened the PFS in each cytogenetic group (p ≤.001), we investigated the unique features of MRD cells persisting after VRD-induction by comparing their transcriptome to that of patient-matched tumor cells at diagnosis (n=40). Accordingly, MRD cells showed 763 genes significantly deregulated (Padj Conclusions: This is one of the largest studies integrating patients' cytogenetics and MRD status. Our results, based on intensive treatment and MRD monitoring using NGF, unveil that achieving MRD-negativity may overcome the poor prognosis of HR cytogenetics. By contrast, persistent MRD significantly reduces PFS rates, particularly in patients with del(17p). Interestingly, MRD cells from SR and HR patients may have different transcriptional mechanisms leading to VRD resistance, and further understanding of these could provide knowledge on how to eradicate MRD in both patient subgroups. Disclosures Puig: Takeda: Consultancy, Honoraria; Celgene: Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding. Garcia-Sanz:Affimed: Research Funding. Martinez-Lopez:BMS: Research Funding; Pfizer: Research Funding; Vivia: Honoraria; Celgene: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Novartis: Research Funding. Oriol:Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Rios:Amgen, Celgene, Janssen, and Takeda: Consultancy. De La Rubia:Ablynx: Consultancy, Other: Member of Advisory Board. Mateos:GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Lahuerta:Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Bladé:Janssen: Honoraria. San-Miguel:Amgen: Honoraria; BMS: Honoraria; Novartis: Honoraria; Sanofi: Honoraria; Celgene: Honoraria; Roche: Honoraria; Janssen: Honoraria.
- Published
- 2018
18. Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial
- Author
-
Ana Jiménez Ubieto, Jesús Martín, Javier de la Rubia, Laura Rosiñol, José Gonzalez Medina, Isabel Krsnik, Joan Bargay, Joaquin Martinez Lopez, María Teresa Cedena, Rafael Rios, María José Calasanz, Luis Palomera, Joan Bladé, Maria-Victoria Mateos, Miguel-Teodoro Hernández, Albert Oriol, Noemi Puig, Juan José Lahuerta, Jesús Blanchard, Enrique M. Ocio, José M. Moraleda, Maria Luisa Martin-Ramos, Bruno Paiva, Jesús F. San-Miguel, and Rafael Alonso Fernández
- Subjects
medicine.medical_specialty ,business.industry ,Stringent Complete Response ,Low resolution ,Immunology ,Cell Biology ,Hematology ,Newly diagnosed ,medicine.disease ,Biochemistry ,Transplantation ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Family medicine ,Landmark analysis ,medicine ,business ,Bristol-Myers ,Multiple myeloma ,030215 immunology - Abstract
Introduction: To discriminate different outcomes among patients in CR, the International Myeloma Working Group (IMWG )introduced more stringent CR (sCR) criteria by adding to the pre-existing CR parameters the requirement of a normal free-light chain ratio (sFLCr) plus the absence of clonal plasma cells (PCs) in bone marrow (BM) by immunohistochemistry (IHC). In 2011,the low-sensitivity cytometrycriteria were included as alternative methodology to IHC to define sCR. Aim: To validate the preliminary data of our previous study (Blood 2015. 126:858-62) regarding the lack of influence of an abnormal sFLCr in the outcome of MM patients, through the analysis of a more extensiveseries of newly diagnosed multiple myeloma (NDMM) patients in CR or sCR. Patients and Methods: This study is based on 459 NDMM patients who were transplant candidates and enrolled in the GEM2012MENOS65phase 3trial;evaluable patients were enrolled in a subsequent maintenance trial (NCT02406144).CR and sCR was defined according to the IMWG criteria. Agreeing to the protocol, patients with 1.65 if the patient was κ). BM aspirates were assessed for morphological enumeration of PCs and monitoring of minimal residual disease (MRD) using next-generation flow (NGF) according toEuroFlow SOPs. The median limit of detection was of 3x10-6. We classified as sCR all patients in CR with normal sFLCr and absence of clonal PCs by NGF with a reduced threshold of sensitivity to 10-4.The median follow-up was 40 months. Results: After ASCT,392 patients were evaluable for response; 239 (61%) reached ≥CR. Data from sFLCr and MRD was available in 225 and 221 patients, respectively. In 153 out of a total of 203 (74%) patients in CR in which complete information about FLC and MRD was available were categorized as sCR. The remaining 55 patients were consider in CR because of failure to accomplish 1 of the 2 criteria: abnormal sFLCr (n=49) or MRD+veby low sensitivity flow (n=11); 5patientsshared both criteria.In a landmark from ASCT, with a follow up of 27 months, sCRdidn't show significantly differences inPFS (2 years-PFS 90% vs 83%; P=.2) neither in OS (2 years-OS 96% vs 98%; P=.6) as compared to CR patients.Interestingly, patients with abnormal (n=51) vs normal (n=174) sFLCr showed superimposable PFS (2 years-PFS 86% vs 88%; P=.6) and OS (2 years-OS 95% vs 100%; P=.2).By contrast, in the 11 patients (out of the 221, 5%) with persistent MRD (>10-4) the PFS was significantly poorer as compared with MRD-ve cases (2-yearsPFS 91% vs48%; P=.001)but the OS was similar (2 years-OS 98% vs 96%; P=.3).As validation, we reproduced the analysis in the consolidation-2 end-point (figure 1), where375patients were evaluable for response assessment,267 of them (71%) reached ≥CR. Once again, in the landmark analysis, sCR didn't show significantly differences in PFS with respect to CR patients (2 years-PFS 88% vs 84%; P=.2) neither in OS (2 years-PFS 96% vs 90%; P=.3); moreover, patients with abnormal (n=55) vs normal (n=195) sFLCr showed superimposable PFS (2 years-PFS 84% vs 87%; P=.4) and OS (2 years-OS 89% vs 96%; P=.2).In the MRD analysis, patients with persistent MRD, had significantly inferior PFS (2-years PFS 87% vs 72%; P=.04 for >10-4 MRDsensitivity). If we increase the sensitivity of the MRD to 10-6, the differences in PFS at 2 years are more evident (2 years-PFS 94% vs 67%; P10-6 sensitivity). Conclusion: These results confirm our previous findings based on GEM05menos65/ GEM10mas65 clinical trials, indicating that for MM patients stringent CR criteria does not predict a different outcome as compared to standard CR. Specifically, the sFLCr doesn't identify patients in CR at distinct risk. If this essential criterion in the definition of sCR lacks connotations for the prognosis, is it not justified to maintain a response category whose real significance depends on the combination of the traditional CR criteria with a negative MRD status based on very low (IHC) or low resolution ( Figure 1. Figure 1. Disclosures Martinez Lopez: Janssen: Research Funding, Speakers Bureau; Bristol Myers Squibb: Research Funding, Speakers Bureau; Novartis: Research Funding, Speakers Bureau; Celgene: Research Funding, Speakers Bureau. Rosinol:Janssen, Celgene, Amgen, Takeda: Honoraria. Puig:Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Oriol:Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Ocio:Pharmamar: Consultancy; AbbVie: Consultancy; Seattle Genetics: Consultancy; BMS: Consultancy; Janssen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Sanofi: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Mundipharma: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Array Pharmaceuticals: Research Funding. De La Rubia:Ablynx: Consultancy, Other: Member of Advisory Board. Rios:Amgen, Celgene, Janssen, and Takeda: Consultancy. Mateos:Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. San-Miguel:Sanofi: Consultancy; Takeda: Consultancy; Novartis: Consultancy; MSD: Consultancy; Janssen: Consultancy; Celgene: Consultancy; Brystol-Myers Squibb: Consultancy; Amgen: Consultancy; Roche: Membership on an entity's Board of Directors or advisory committees. Bladé:Amgen: Honoraria; Celgene: Honoraria; Janssen: Honoraria. Lahuerta:Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees.
- Published
- 2018
19. Understanding the Cellular Origin and Pathogenic Transcriptional Programs in Multiple Myeloma (MM) and Light-Chain Amyloidosis (AL) through the Dissection of the Normal Plasma Cell (PC) Development
- Author
-
Amaia Vilas-Zornoza, Jesús F. San-Miguel, María José Casanova, Ibai Goicoechea, Marta Lasa, Ramón Lecumberri, Jorge Labrador, Alfonso García de Coca, Albert Pérez, Diego Alignani, Assaf Weiner, Maria-Victoria Mateos, Daniel Alameda, Idoia Rodriguez, Bruno Paiva, Marco Vicari, Esther González Garcia, David Lara-Astiaso, Felipe Prosper, Valentin Cabañas, Isabel Krsnik, Albert Oriol, Noemi Puig, Joaquin Martinez Lopez, Maria Teresa Cedena Romero, Juan José Lahuerta, Mercedes Gironella, Ido Amit, Enrique M. Ocio, Luis Palomera, and Sarai Sarvide
- Subjects
Amyloidosis ,Immunology ,Cell Biology ,Hematology ,Dissection (medical) ,Plasma cell ,Biology ,medicine.disease ,Immunoglobulin light chain ,Biochemistry ,Cellular origin ,medicine.anatomical_structure ,medicine ,Cancer research ,Multiple myeloma - Abstract
Background: MM and AL are the two most common malignant monoclonal gammopathies. Both diseases result from the accumulation of clonal PCs, but their clinical behavior is significantly different suggesting fundamental differences in disease biology. Previous attempts to identify genetic hallmarks that could explain such differences have been unsuccessful. Furthermore, it is unknown if MM and AL arise from the same or different normal PC counterparts. Aim: To define a transcriptional atlas of the normal PC development in peripheral blood (PB) and bone marrow (BM) for comparison with the transcriptional programs of clonal PCs in MM and AL. Methods: A total of 93 subjects were studied. In 7 healthy adults (HA), PB PCs were phenotypically sorted according to heavy-chain isotypes (IgG, IgA and IgM). In addition, 5 different BM PCs subsets were isolated based on the differential expression of CD19, CD39, CD81 and CD56, due to their ascribed role in dissecting unique BM PC differentiation states. Clonal PCs from patients with MM (n=38) and AL (n=41) were isolated by FACS according to patient-specific aberrant phenotypes. Due to small numbers of PCs sorted from each subset in HA and clonal PCs in AL patients, we used an RNAseq method optimized for limited cell numbers. Differential expression across all pairwise comparisons between groups was analyzed with Deseq2 R package followed by k-means clustering of genes in R. Single-cell RNAseq (scRNAseq, 10xGenomics) was performed in a total of 35,910 PCs from 3 HA, 2 MM and 2 AL. We used Seurat R package to remove batch effect followed by canonical correlation to perform an integrated analysis of all single PCs from HA, MM and AL subjects. Results: Principal component analysis of RNAseq data unveiled two major clusters of normal PCs: those in PB and those in BM (with some transcriptional diversity between CD19+ and CD19- PCs), whereas the CD19+CD39+CD81+CD56- BM subset co-localized with PB and CD39- BM PCs (Panel A). Clonal PCs from MM and AL patients clustered together, and both displayed some transcriptional variance related to the spatial location of normal PCs (i.e. PB or BM). In total, 2174 genes were found significantly deregulated after cross-comparing the 10 PC groups (adj.p-value1) and semi-supervised k-means clustering unveiled 8 transcriptional modules (Panel B). Namely, the transition from PB into BM PCs was characterized by genes related to proliferation (clusters 1 & 2), whereas CD39+ and CD39- BM PC subsets differed on the expression of genes associated with proliferation, homing, and metabolism (1, 2, 4 & 6). Thus, CD19+CD39+CD81+CD56- BM PCs emerged as a novel subset that bridges new-born PB with long-lived (CD39-) BM PCs. Interestingly, clonal PCs from MM and AL shared transcriptional programs related to quiescence (5 & 6) with long-lived BM PCs; however, skewing of polyclonal immunoglobulin gene expression (3) and active gene transcription (8) emerged as hallmarks of the neoplastic transformation from normal, long-lived PCs into clonal PCs. That notwithstanding, the later displayed expression levels of the proliferation and homing transcriptional modules (1 & 4) similar to new-born PB and CD39+ BM PCs. Of note, a small transcriptional cluster of genes related to ribosome biogenesis (7) was significantly more expressed in MM than AL. These findings led us to integrate scRNAseq profiles of normal and clonal BM PCs from MM and AL patients, to define PC clusters based on their transcriptional program rather than their normal vs malignant status (Panel C). This strategy unveiled 11 different PC clusters with unequal distribution between groups. Thus, more than half of clonal PCs in MM and AL were assigned to a cluster that is also predominant in normal PCs (1). By contrast, other clusters with a transcriptional program similar to that of new-born PCs (2 & 5) became rarer in MM and AL. Furthermore, a cluster of PCs with an immature-like phenotype (6) was detectable in MM but almost absent in AL. Conclusions: This is the first integrated analysis of the transcriptional programs of normal PC subsets and clonal PCs in MM and AL, both at the bulk and single-cell levels. Our results unveil shared and exclusive transcriptional states in normal and clonal PCs, together with unique differences between clonal PCs in MM and AL. Thus, we provide here a fundamental resource to understand normal PC development and the cellular origin of both malignant monoclonal gammopathies. Figure Figure. Disclosures Puig: Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Ocio:Pharmamar: Consultancy; AbbVie: Consultancy; Janssen: Consultancy, Honoraria; Seattle Genetics: Consultancy; BMS: Consultancy; Takeda: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Sanofi: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Mundipharma: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Array Pharmaceuticals: Research Funding. Oriol:Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Martinez Lopez:Bristol Myers Squibb: Research Funding, Speakers Bureau; Janssen: Research Funding, Speakers Bureau; Novartis: Research Funding, Speakers Bureau; Celgene: Research Funding, Speakers Bureau. Mateos:Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees. Lahuerta:Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. San-Miguel:Sanofi: Consultancy; Takeda: Consultancy; Novartis: Consultancy; MSD: Consultancy; Janssen: Consultancy; Celgene: Consultancy; Brystol-Myers Squibb: Consultancy; Amgen: Consultancy; Roche: Membership on an entity's Board of Directors or advisory committees.
- Published
- 2018
20. Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM)
- Author
-
Dolores Gómez, María-Belén Vidriales, Albert Pérez, Luis Palomera, Alfonso García de Coca, Bruno Paiva, Maria-Victoria Mateos, Joaquin Martinez Lopez, Juana Merino, Cristina Moreno, Felipe de Arriba, Jorge Labrador, Felipe Prosper, Mercedes Gironella, Albert Oriol, Ramón Lecumberri, María Teresa Cedena, Quentin Lecrevisse, Esther González Garcia, Jesús F. San-Miguel, María José Casanova, Enrique M. Ocio, Marta Lasa, José J. Pérez, Juan José Lahuerta, Javier Verde, Noemi Puig, Alberto Orfao, Jose Enrique de la Puerta, Valentin Cabañas, Isabel Krsnik, Javier de la Rubia, and Leire Burgos
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Tumor burden ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Organ damage ,Immunophenotyping ,Internal medicine ,medicine ,Organ involvement ,Diagnostic screening ,business ,Bristol-Myers ,Monoclonal gammopathy of undetermined significance ,Multiple myeloma - Abstract
Background: Since survival in AL mainly depends on the extent of organ involvement of patients at presentation, early diagnosis and risk stratification are key to improve patients' outcome. Therefore, together with surrogates of organ involvement, biomarkers identifying patients with MGUS or MM at greater risk of developing AL would be highly valuable to prevent organ damage, to maximize therapeutic efficacy and to improve outcomes in AL. Aim: To investigate the value of multidimensional flow cytometry (MFC) for simultaneous fast diagnostic screening of plasma cell (PC) clonality and risk stratification, as well as to identify immunophenotypic markers useful for the selection of patients with monoclonal gammopathies candidates for monitoring of pre-symptomatic organ damage related to AL. Methods: We used MFC to characterize a large series of patients with newly-diagnosed (ND) AL (N=94) vs MGUS (N=20) and NDMM (N=52), as well as age-matched healthy adults (HA, N=30). For each patient with AL, automated risk stratification was performed using principal component analysis (PCA) based on the relative frequency of bone marrow (BM) PCs, plus the percentage of clonal and normal PCs within the whole BM PC compartment, vs a database containing information on the same three parameters from a total of 1,774 patients, including 497 MGUS and 1,227 NDMM. In parallel, immunophenotypic protein expression profiles (iPEP) of AL patients were clustered using t-SNE, and the comparison between the iPEP of clonal PCs from patients with AL vs MGUS and MM cases was performed using canonical-correlation analysis (CCA). To identify additional immunophenotypic hallmarks of AL, the BM cellular composition in HA, MGUS, AL and MM patients was compared using 2-dimensional minimum spanning tree (MST) force-directed classification to determine the distance among individual cases. Results: PC clonality was detected by MFC in 93/94 (99%) AL patients, whereas an M-component was detectable in 96% of cases by electrophoresis, immunofixation and sFLC. PCA as defined above, identified AL patients displaying an MM-like (n=6) and an MGUS-like (n=38) signature, as well as 49 cases with an intermediate signature between the MGUS and MM reference datasets. Multivariate analysis of baseline prognostic factors for survival, including patients' age, number of organs involved, Mayo staging, the percentage of BM PCs based on cytomorphology and eligibility for ASCT, showed that having an intermediate- or an MM-like profile had an independent adverse effect on patients' progression-free (PFS) and overall survival (OS) (HR:3.4; P≤.02). t-SNE based on the iPEP of clonal PCs revealed two major clusters of AL patients with significantly different PFS, defined by opposite patterns of expression for CD45, CD56 and CD138 (P≤.02). CCA of tumor iPEP showed partial overlap between AL vs MGUS and MM, with progressively higher percentages of cases with a CD38lo, CD45-ve, CD81-ve and CD138lo iPEP being observed from MGUS to AL and MM. In contrast, AL patients displayed significantly lower reactivity for CD56 (P≤ .03). Further characterization of the BM cellular composition allowed the systematic assessment of 16 cell populations and 18 phenotypic parameters that, by MST, mapped AL in between MGUS and MM. Of note, while AL patients displayed a predominantly-clonal PC compartment in the absence of an MM-like tumor PC expansion, the percentage of B-cell precursors was consistently lower in AL patients than in HA, MGUS and MM (P=.004). Thus, using optimal cut-off values to discriminate between AL vs MGUS and MM, we built a scoring model based on the presence of 80% clonal PCs within total BM PCs and Conclusions: We demonstrate the value of MFC for fast diagnostic screening of PC clonality in AL and simultaneous automated patient risk-stratification, based on the BM tumor burden and PC phenotype. In addition, our results also provide new immunophenotypic markers for the identification of patients with monoclonal gammopathies that are candidates for monitoring of pre-symptomatic organ damage related to AL. Disclosures Puig: Janssen: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria; Celgene: Honoraria, Research Funding. Ocio:Array Pharmaceuticals: Research Funding; Sanofi: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Pharmamar: Consultancy; BMS: Consultancy; AbbVie: Consultancy; Janssen: Consultancy, Honoraria; Seattle Genetics: Consultancy; Mundipharma: Research Funding; Takeda: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Oriol:Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. De La Rubia:Ablynx: Consultancy, Other: Member of Advisory Board. Martinez Lopez:Janssen: Research Funding, Speakers Bureau; Celgene: Research Funding, Speakers Bureau; Novartis: Research Funding, Speakers Bureau; Bristol Myers Squibb: Research Funding, Speakers Bureau. Mateos:Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Lahuerta:Janssen: Honoraria; Celgene: Honoraria; Amgen: Honoraria.
- Published
- 2018
21. Association of DDX58 177 C T polymorphism with decreased risk of Epstein-Barr virus-related nodular sclerosis classical Hodgkin lymphoma
- Author
-
Paloma Martín, Manuela Moraru, Isabel Krsnik, Carmen Bellas, Jimena Martinez-Velasquez, Carlos Vilches, María José Coronado, Natalia Gómez-Lozano, Mariano Provencio, and Belen Navarro
- Subjects
0301 basic medicine ,Adult ,Male ,Cancer Research ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,Adolescent ,Genotype ,Single-nucleotide polymorphism ,macromolecular substances ,Biology ,medicine.disease_cause ,Polymorphism, Single Nucleotide ,Virus ,03 medical and health sciences ,Young Adult ,Nodular sclerosis ,Gene Frequency ,Interferon ,hemic and lymphatic diseases ,medicine ,Genetic predisposition ,Odds Ratio ,Humans ,Genetic Predisposition to Disease ,Receptors, Immunologic ,Nodular Sclerosis Classical Hodgkin Lymphoma ,Epstein–Barr virus infection ,Alleles ,Aged ,Sclerosis ,Hematology ,Middle Aged ,medicine.disease ,Cell Transformation, Viral ,Epstein–Barr virus ,Hodgkin Disease ,030104 developmental biology ,Oncology ,Case-Control Studies ,Immunology ,DEAD Box Protein 58 ,Female ,medicine.drug - Abstract
Classical Hodgkin lymphoma (cHL) is frequently related to Epstein-Barr virus (EBV) infection. Its malignant capacity is attributed to disruption of an EBV-host balance influenced by environmental and genetic drivers. EBV structures activate Type I interferon (IFN) pathway of the innate immunity, therefore, genetic polymorphisms could influence this response. We explored the impact of four single nucleotide polymorphisms (SNPs) on EBV-associated cHL susceptibility. Toll-like receptors 9 (TLR9_rs5743836), and 3 (TLR3_rs3775291), Interleukin-28B (IL28B_rs12979860), and DEAD-box polypeptide 58 (DDX58_rs10813831) were genotyped in 73 EBV-positive and 106 EBV-negative cHL patients and 396 controls. Only DDX58_rs10813831 T-allele was decreased among EBV-positive cHL compared to controls. A stratified analysis in EBV-positive cHL showed that the reduced rate was associated with younger age and nodular sclerosis. In conclusion, DDX58_rs10813831 T-allele may be associated with a reduced risk of nodular sclerosis EBV-related cHL, which suggests a role for RIG-I (retinoic acid-inducible gene I), encoded by DDX58, in these cases.
- Published
- 2016
22. Immune reconstitution after cord blood transplants supported by coinfusion of mobilized hematopoietic stem cells from a third party donor
- Author
-
Rafael Cabrera, Isabel Krsnik, Miguel A. Rico, Belen Navarro, Guiomar Bautista, M N Fernández, Rosa Gonzalo-Daganzo, N Pérez-Sanz, Isabel Millán, Carmen Regidor, Santiago Gil, José A. García-Marco, Emilio Ojeda, Rafael Fores, N. Panadero, Rocio Sanchez, Sanjuán I, Elena Ruiz, Trinidad Martín-Donaire, and Elena Magro
- Subjects
Adult ,Male ,Transplantation Conditioning ,medicine.medical_treatment ,Graft vs Host Disease ,Kaplan-Meier Estimate ,Cord Blood Stem Cell Transplantation ,Hematopoietic stem cell transplantation ,Lymphocyte Activation ,Disease-Free Survival ,Young Adult ,Immune system ,Transplantation Immunology ,Living Donors ,medicine ,Humans ,Hematopoietic Stem Cell Mobilization ,Transplantation ,business.industry ,Histocompatibility Testing ,Graft Survival ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Haematopoiesis ,Hematologic Neoplasms ,Cord blood ,Immunology ,Female ,Stem cell ,business - Abstract
Low severity of GVHD, substantial graft vs tumor (GVT) and slow development of protective immunity are well-documented features of cord blood transplants (CBT). We have evaluated the immune reconstitution of adult recipients of single-unit CBT supported by the coinfusion of third party donor (TPD) mobilized hematopoietic stem cells (MHSC), a procedure-'dual CB/TPD-MHSC transplant'-that results in early recovery of circulating granulocytes, high rates of CB engraftment and full chimerism. Cumulative recovery of natural killer and B cells at or above the median values of normal controls were 1.0 and 0.76 by the sixth and ninth months. Recovery of T cells was much slower, naive cells lagging behind those of memory and effector (committed) immunophenotypes. Serial analyses of signal joint TCR excision circles showed a general pattern of very low levels by the third month after CBT, followed by recovery to levels persistently similar or higher than those observed before transplantation and in normal controls. Our results are consistent with the clinical observations of substantial GVT effect together with low incidence of serious GVHD and slow development of protective immunity and suggest that thymic function contributes substantially to the recovery of T-cell populations in adults receiving dual CB/TPD-MHSC transplants.
- Published
- 2009
23. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor
- Author
-
Isabel Krsnik, Rosa Gonzalo-Daganzo, Rafael Fores, Isabel Millán, M N Fernández, José A. García-Marco, Elena Ruiz, Belen Navarro, Emilio Ojeda, Elena Magro, Carmen Regidor, Miguel A. Rico, Guiomar Bautista, A de Laiglesia, Trinidad Martín-Donaire, Santiago Gil, Sanjuán I, and J R Cabrera
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,CD34 ,Graft vs Host Disease ,Gastroenterology ,Umbilical cord ,Internal medicine ,medicine ,Humans ,Transplantation ,Hematology ,business.industry ,Histocompatibility Testing ,Incidence (epidemiology) ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,Hematopoietic Stem Cell Mobilization ,Tissue Donors ,Surgery ,Haematopoiesis ,medicine.anatomical_structure ,Cord blood ,Female ,Cord Blood Stem Cell Transplantation ,Stem cell ,business - Abstract
This open label clinical study provides updated evaluation of the strategy of single unit cord blood transplants (CBTs) with co-infusion of third-party donor (TPD) mobilized hematopoietic stem cells (MHSC). Fifty-five adults with high-risk hematological malignancies, median age 34 years (16-60 years) and weight 70 kg (43-95 kg), received CBTs (median 2.39 x 10(7) total nucleated cell (TNC) per kg and 0.11 x 10(6) CD34+ per kg) and TPD-MHSC (median 2.4 x 10(6) CD34+ per kg and 3.2 x 10(3) CD3+ per kg). Median time to ANC and to CB-ANC0.5 x 10(9)/l as well as to full CB-chimerism was 10, 21 and 44 days, with maximum cumulative incidences (MCI) of 0.96, 0.95 and 0.91. Median time to unsupported platelets20 x 10(9)/l was 32 days (MCI 0.78). MCI for grades I-IV and III-IV acute GVHD (aGVHD) were 0.62 and 0.11; 12 of 41 patients (29%) who are at risk developed chronic GVHD, becoming severely extensive in three patients. Relapses occurred in seven patients (MCI=0.17). The main causes of morbi-mortality were post-engraftment infections. CMV reactivations were the most frequent, their incidence declining after the fourth month. Five-year overall survival and disease-free survival (Kaplan-Meier) were 56 % and 47% (63% and 54% for patientsor=40 years). In conclusion, CBT with single units of relatively low cell content and 0-3 HLA mismatches is feasible as a first choice option for adult patients who lack a readily available adequate adult donor.
- Published
- 2008
24. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies
- Author
-
Miguel A, Sanz, Pau, Montesinos, Haesook T, Kim, Guillermo J, Ruiz-Argüelles, María S, Undurraga, María R, Uriarte, Lem, Martínez, Rafael H, Jacomo, Homero, Gutiérrez-Aguirre, Raul A M, Melo, Rosane, Bittencourt, Ricardo, Pasquini, Katia, Pagnano, Evandro M, Fagundes, Edo, Vellenga, Alexandra, Holowiecka, Ana J, González-Huerta, Pascual, Fernández, Javier, De la Serna, Salut, Brunet, Elena, De Lisa, José, González-Campos, José M, Ribera, Isabel, Krsnik, Arnold, Ganser, Nancy, Berliner, Raul C, Ribeiro, Francesco, Lo-Coco, Bob, Löwenberg, Eduardo M, Rego, E, de Lisa, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), and Hematology
- Subjects
Oncology ,Male ,medicine.medical_treatment ,Risk-adapted therapy ,Pharmacology ,THERAPY ,Leukemia, Promyelocytic, Acute ,immune system diseases ,Risk Factors ,Antineoplastic Combined Chemotherapy Protocols ,Cumulative incidence ,Anthracyclines ,Adolescent ,Adult ,Aged ,Daunorubicin ,Disease-Free Survival ,Female ,Humans ,Idarubicin ,Matched-Pair Analysis ,Middle Aged ,Treatment Outcome ,Tretinoin ,Young Adult ,CONSOLIDATION ,Promyelocytic ,OUTCOMES ,Leukemia ,Cytarabine ,Hematology ,General Medicine ,Cohort ,medicine.drug ,medicine.medical_specialty ,Anthracycline ,AGENT ARSENIC TRIOXIDE ,Acute ,Matched-pair analysis ,Prognostic factors ,Internal medicine ,medicine ,neoplasms ,RESPONSE CRITERIA ,Chemotherapy ,business.industry ,All-trans retinoic acid ,QUIMIOTERÁPICOS ,ANTHRACYCLINE ,medicine.disease ,Acute promyelocytic leukaemia ,business ,Settore MED/15 - Malattie del Sangue - Abstract
Front-line treatment of acute promyelocytic leukaemia (APL) consists of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy. In this setting, a comparison of idarubicin and daunorubicin has never been carried out. Two similar clinical trials using ATRA and chemotherapy for newly diagnosed APL were compared using matched-pair analysis. One was conducted by the PETHEMA/HOVON group with idarubicin and the other by the International Consortium on APL (IC-APL) using daunorubicin. Three hundred and fifty patients from the PETHEMA/HOVON cohort were matched with 175 patients in the IC-APL cohort, adjusting for the significantly unbalanced presenting features of the two entire cohorts. Complete remission (CR) rate was significantly higher in the PETHEMA/HOVON (94 %) than in the IC-APL cohort (85 %) (P = 0.002). The distribution of causes of induction failure and the time to achieve CR were similar in both cohorts. Patients who achieved CR had comparable cumulative incidence of relapse and disease-free survival rates, but lower overall and event-free survivals were observed in the IC-APL cohort, which was mainly due to a higher death rate during induction therapy. A higher death rate during consolidation therapy was also observed in the IC-APL. These results show that daunorubicin and idarubicin have similar antileukaemic efficacy in terms of primary resistance, molecular persistence, as well as molecular and haematological relapse rates when combined with ATRA in treatment of APL. However, a higher toxic death rate during induction and consolidation therapy was observed in the IC-APL cohort. This trial was registered at www.clinicaltrials.gov as #NCT00408278 [ClinicalTrials.gov].
- Published
- 2015
25. Hemophagocytic syndrome associated with retinoic acid syndrome in acute promyelocytic leukemia
- Author
-
Eduardo Reyes, J. Garcia-Suarez, Helena Bañas, Isabel Krsnik, Carmen Burgaleta, and D. De Miguel
- Subjects
Acute promyelocytic leukemia ,medicine.medical_specialty ,Hematology ,business.industry ,Hepatosplenomegaly ,medicine.disease ,Pancytopenia ,Retinoic acid syndrome ,Leukemia ,medicine.anatomical_structure ,hemic and lymphatic diseases ,Internal medicine ,Immunology ,medicine ,Idarubicin ,Bone marrow ,medicine.symptom ,business ,neoplasms ,medicine.drug - Abstract
A 56-year-old woman with an acute promyelocytic leukemia (APL) developed a severe all-trans-retinoic (ATRA) syndrome on day 17 of treatment. Shortly after, she presented a picture of pancytopenia, hepatosplenomegaly, increased triglycerides, ferritin, and liver enzymes. A bone marrow biopsy showed abundant macrophages and no evidence of leukemia. Tests for secondary hemophagocytic syndrome (HPS) were negative. A diagnosis of HPS was made. Treatment with dexamethasone and high-dose immunoglobulins was unsuccessful. Consolidation chemotherapy with idarubicin and ATRA rapidly reversed the HPS. The HPS in this patient could be related to the release of macrophage-stimulating cytokines by APL cells during ATRA syndrome.
- Published
- 2004
26. Elderly haematological patients with chemotherapy-induced febrile neutropenia have similar rates of infection and outcome to younger adults: a prospective study of risk-adapted therapy
- Author
-
Eduardo Reyes, Nuria Hernanz, J. Garcia-Suarez, Carmen Burgaleta, Isabel Krsnik, Dunia de Miguel, and Mohamed Barr-Alí
- Subjects
medicine.medical_specialty ,Leukopenia ,business.industry ,Incidence (epidemiology) ,Hematology ,Neutropenia ,medicine.disease ,Surgery ,Amikacin ,Internal medicine ,medicine ,Absolute neutrophil count ,medicine.symptom ,Prospective cohort study ,business ,Complication ,Febrile neutropenia ,medicine.drug - Abstract
Summary. We prospectively evaluated 131 consecutive episodes of fever and chemotherapy-induced neutropenia in 85 adults with haematological malignancies to determine whether older patients (aged
- Published
- 2003
27. Spontaneous gas gangrene in malignant lymphoma: An underreported complication?
- Author
-
Isabel Krsnik, Mohammed Barr-Alí, J. Garcia-Suarez, Dunia de Miguel, Nuria Hernanz, and Carmen Burgaleta
- Subjects
medicine.medical_specialty ,business.industry ,Opportunistic infection ,Induction chemotherapy ,Hematology ,Neutropenia ,medicine.disease ,Dermatology ,Lymphoma ,Surgery ,Malignant lymphoma ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Clostridial infection ,business ,Complication ,Gas gangrene - Abstract
We report a case of spontaneous gas gangrene (SGG), the most rapidly progressive form of clostridial infection, in a patient with non-Hodgkin's lymphoma (NHL). We review the literature and examine the association between these two entities. A 43-year-old man with NHL developed fatal C. perfringens-associated SGG and massive hemolysis during induction chemotherapy. Although patients with NHL usually have several risk factors of SGG, such as bowel involvement or neutropenia, only two cases have been described previously in detail. Common features of all reports are a delayed diagnosis and a fatal outcome. Awareness of this condition should result in prompt antibiotic therapy at the onset of typical presenting symptoms in any lymphoma patient, especially if risk factors are present.
- Published
- 2002
28. The contribution of f. w. peabody to the study of pernicious anaemia
- Author
-
Isabel Krsnik
- Subjects
Ineffective erythropoiesis ,medicine.medical_specialty ,Pernicious anaemia ,business.industry ,Internal medicine ,Medicine ,Hematology ,business ,medicine.disease_cause ,Gastroenterology - Published
- 2001
29. Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study
- Author
-
Laura Rosiñol, Gonzalo Gutierrez, Antonia Sampol, Carmen Martinez, Cristina Castilla-Llorente, Maria-Victoria Mateos, Francesc Fernández-Avilés, José Antonio Pérez-Simón, Veronica D. Gonzalez, Isabel Krsnik, Mireia Morgades, A. M. Vazquez, José M. Moraleda, José Rifón, Josep-Maria Ribera, Oriana Lopez Godino, Inmaculada Heras, Martin Cabero, Teresa Caballero Velázquez, Marta Torres Juan, Pastora Iniesta, Lucía López Corral, Montserrat Rovira, Daniel Morillo, Dolores Caballero, and Jesus San Miguel
- Subjects
Oncology ,Melphalan ,medicine.medical_specialty ,Allogeneic transplantation ,Immunology ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Multiple myeloma ,030219 obstetrics & reproductive medicine ,business.industry ,Cell Biology ,Hematology ,Pomalidomide ,medicine.disease ,Carfilzomib ,Fludarabine ,Transplantation ,Calcineurin ,chemistry ,business ,030215 immunology ,medicine.drug - Abstract
Introduction: Allogeneic haematopoietic stem cell transplantation (alloHCT) is a potentially curative approach for patients (pts) with multiple myeloma (MM). The high transplant related mortality (TRM) rate with myeloablative conditioning has resulted in a shift to reduced intensity conditioning regimens (RIC). However, most MM pts who receive an alloRIC ultimately relapse and their treatment remains a challenge. Since alloHCT can modify the biology of the disease, including the immune environment, responses after alloHCT to rescue therapies previously used before alloHCT could be improved. Our main objective was to evaluate the efficacy of regimens including new drugs in MM pts relapsing after alloHCT comparing the efficacy achieved before and after alloHCT. Material and Methods: We report a retrospective multicenter analysis of 126 consecutive pts that underwent alloHCT for MM from 2010 to 2013 at 8 Spanish centers. Results: Baseline pts and transplant characteristics are shown in Table I. The median of prior therapies prior to alloHCT was 3 (1-9), 83% had received previous autologous HCT and 26% had high risk cytogenetic. 71 (56%) and 48 pts (38%) had been treated with regimens containing proteasome inhibitors (PI) and immunomodulatory drugs (IMIDs) before transplantation, respectively. Disease status at transplant was complete remission (CR) in 16 (13%) pts, partial response (PR) or very good PR in 86 (68%) and 24 (18.5%) had relapsed/progressive disease. 35 pts (28%) had active extramedullary disease at transplant. The majority of pts received peripheral blood HCT (90%), RIC (90%) with fludarabine plus melphalan based conditioning regimen (61%) and calcineurin inhibitor plus MTX as GVHD prophylaxis (68%). 19% receiving allo-HCT from an unrelated donor (91% 10/10 HLA matched). All pts engrafted. Grade II-IV acute GVHD occurred in 54% pts (grade IV 8%) and chronic GVHD in 45% (moderate 15%, severe 12%). TRM within the first 100 days after transplant was 6% (overall TRM 28%). 60% pts improved their pre-transplant response, with an overall response rate of 74% (56% CR). After a median follow-up of 92 months for pts alive (22-197), the OS was 51 and 43% at 2 and 5 years respectively. 75 pts (59.5%) relapsed after alloHCT, 57 of them with extramedullary involvement. Median time to relapse was 8 months post-transplant (1-141). The cumulative incidence of relapse was 79% at 3 years. Median OS after relapse was 22 months (8-33). Seventeen out of 75 pts who relapsed received IP both in the pre-transplant and in the post-transplant period. Sixteen pts out of 17 who received IP achieved at least PR pre-transplant while 10 out of these 16 pts responded again to PI post-HCT. Moreover, 1 patient reached a deeper response (CR) post as compared to pre alloHCT (PR) and 1 patient who was refractory pre-alloHCT did respond post-alloHCT. In addition, 6 out of 7 pts who did not respond to IP post-transplant reached stable disease with time to progression (TTP) lasting 4 to 12 months. Twelve out of 75 pts who relapsed received IMIDs both pre and post-alloHCT. Ten pts out of 12 who received IMID pre-alloHCT achieved at least PR, and 8 out of these 10 pts responded again to IMIDs post-alloHCT. Moreover, 1 patient who had been refractory to IMIDs in the pre-transplant period reached CR after alloHCT. In addition, 2 out of 4 pts who were refractory to IMIDs in the post-transplant period reached stable disease with TTP of 8 to 13 months. Remarkably, among pts who respond both in the pre and the post-transplant period to IP or IMIDs, the time to response (TTR) and time to progression (TTP) was similar despite the regimens used in the pre-transplant setting were more aggressive (TTR 3 vs 3.5 and TTP 9 vs 7 months before and after alloHCT for IP, and TTR 4 both before and after alloHCT and TTP 10 vs 9.5 months before and after alloHCT for IMIDs). All but 2 pts received first generation IP pre and post-alloHCT (two pts received carfilzomib) and all but 5 received first generation IMIDs (5 pts were treated with pomalidomide). Conclusions: MM pts relapsing after alloHCT should be considered candidates to receive new drugs, as they can achieve response rates at least in a similar proportion and durability to those observed in the pre-transplant setting. This finding is in contrast to the usual course of the disease outside the alloHCT setting, where response rates and TTP decreases with consecutive lines of treatment. Disclosures Mateos: Janssen: Honoraria; Celgene: Honoraria; Takeda: Honoraria; Amgen: Honoraria.
- Published
- 2016
30. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
- Author
-
Pau, Montesinos, Chelo, Rayón, Edo, Vellenga, Salut, Brunet, José, González, Marcos, González, Aleksandra, Holowiecka, Jordi, Esteve, Juan, Bergua, José D, González, Concha, Rivas, Mar, Tormo, Vicente, Rubio, Javier, Bueno, Félix, Manso, Gustavo, Milone, Javier, de la Serna, Inmaculada, Pérez, Manuel, Pérez-Encinas, Isabel, Krsnik, Josep M, Ribera, Lourdes, Escoda, Bob, Lowenberg, Miguel A, Sanz, M, van Marwijk Kooy, Interne Geneeskunde, RS: CARIM School for Cardiovascular Diseases, Hematology, Faculteit Medische Wetenschappen/UMCG, Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Stem Cell Aging Leukemia and Lymphoma (SALL)
- Subjects
Oncology ,Male ,medicine.medical_treatment ,Biochemistry ,PROGNOSTIC-FACTORS ,Leukemia, Promyelocytic, Acute ,COMPETING RISK ,immune system diseases ,Recurrence ,Risk Factors ,Antineoplastic Combined Chemotherapy Protocols ,FAILURE ,Anthracyclines ,CONSOLIDATION ,PETHEMA ,ABNORMALITIES ,hemic and immune systems ,Hematology ,CHEMOTHERAPY ,Middle Aged ,Prognosis ,CD56 Antigen ,Leukemia ,Female ,medicine.drug ,Acute promyelocytic leukemia ,Adult ,medicine.medical_specialty ,Adolescent ,Immunology ,chemical and pharmacologic phenomena ,Tretinoin ,ACUTE MYELOID-LEUKEMIA ,Young Adult ,Internal medicine ,medicine ,Idarubicin ,Humans ,Clinical significance ,INDICATOR ,neoplasms ,Mitoxantrone ,Chemotherapy ,business.industry ,Cell Biology ,medicine.disease ,RISK-ADAPTED TREATMENT ,Cytarabine ,business - Abstract
The expression of CD56 antigen in acute promyelocytic leukemia (APL) blasts has been associated with short remission duration and extramedullary relapse. We investigated the clinical significance of CD56 expression in a large series of patients with APL treated with all-trans retinoic acid and anthracycline-based regimens. Between 1996 and 2009, 651 APL patients with available data on CD56 expression were included in 3 subsequent trials (PETHEMA LPA96 and LPA99 and PETHEMA/HOVON LPA2005). Seventy-two patients (11%) were CD56+ (expression of CD56 in ≥ 20% leukemic promyelocytes). CD56+ APL was significantly associated with high white blood cell counts; low albumin levels; BCR3 isoform; and the coexpression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. For CD56+ APL, the 5-year relapse rate was 22%, compared with a 10% relapse rate for CD56− APL (P = .006). In the multivariate analysis, CD56 expression retained the statistical significance together with the relapse-risk score. CD56+ APL also showed a greater risk of extramedullary relapse (P < .001). In summary, CD56 expression is associated with the coexpression of immaturity-associated and T-cell antigens and is an independent adverse prognostic factor for relapse in patients with APL treated with all-trans-retinoic acid plus idarubicin–derived regimens. This marker may be considered for implementing risk-adapted therapeutic strategies in APL. The LPA2005 trial is registered at http://www.clinicaltrials.gov as NCT00408278.
- Published
- 2010
31. Outcome of Patients with Extramedullary Plasmacytomas (EMPs) Included in a Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)
- Author
-
Ana-Isabel Teruel, Laura Rosiñol, J.J. Lahuerta, Jose Francisco Tomas, J. Bladé, D. Hernández, Belén Iñigo, R. Jiménez, M.V. Mateos, Isabel Krsnik, Miguel-Teodoro Hernández, J. dela Rubia, Norma C. Gutiérrez, Luis Palomera, J F San Miguel, and M.J. Blanchard
- Subjects
Gynecology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Hematology ,medicine.disease ,Surgery ,Autologous stem-cell transplantation ,Oncology ,Induction therapy ,medicine ,business ,geographic locations ,Multiple myeloma - Abstract
e100 PO-033 Outcome of Patients with Extramedullary Plasmacytomas (EMPs) Included in a Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) R. Jimenez, L. Rosinol, A.I. Teruel, J. dela Rubia, M.V. Mateos, M.T. Hernandez, D. Hernandez, M.J. Blanchard, B. Inigo, L. Palomera, I. Krsnik, J.F. Tomas, N.C. Gutierrez, J. San Miguel, J.J. Lahuerta, J. Blade on behalf of Grupo Espanol de Mieloma (PETHEMA/GEM) Hematology, IDIBAPS,Hospital Clinic,Barcelona, Spain; Hospital Clinico Universitario de Valencia, Valencia, Spain; Hospital Universitario la Fe, Valencia, Spain; Hospital universitario de salamancaIBSAL, Salamanca, Spain; Servicio de Hematologia Clinica, Hospital Universitario de Canarias, Tenerife, Spain; Hospital La Paz, Madrid, Spain; Hematology, Hospital Ramon y Cajal, Madrid, Spain; Hematology, Hospital Clinico San Carlos, Madrid, Spain; Hematology, Hospital Lozano Blesa, Zaragoza, Spain; Hematology, Hospital Puerta de Hierro Majadahonda, Mjadahonda, Spain; HematologyBMT Unit, MD Anderson Spain, Madrid, Spain; Hospital Universitario de Salamanca;Centro de Investigacion del Cancer (CIC, IBMCC USAL-CSIC, Salamanca, Spain; Hematology, Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hematology, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain
- Published
- 2015
32. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies
- Author
-
Dunia de Miguel, J. Garcia-Suarez, Helena Bañas, Carmen Burgaleta, Ignacio Arribas, and Isabel Krsnik
- Subjects
Adult ,Male ,medicine.medical_specialty ,Alkylating Agents ,Chronic lymphocytic leukemia ,medicine.medical_treatment ,Purine analogue ,Lymphoproliferative disorders ,Antineoplastic Agents ,Hematopoietic stem cell transplantation ,Gastroenterology ,History, 21st Century ,Disease-Free Survival ,Antibodies, Monoclonal, Murine-Derived ,Sex Factors ,Risk Factors ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Aged ,Retrospective Studies ,Univariate analysis ,Radiotherapy ,business.industry ,Progressive multifocal leukoencephalopathy ,Age Factors ,Leukoencephalopathy, Progressive Multifocal ,Antibodies, Monoclonal ,HIV ,Hematology ,History, 20th Century ,Middle Aged ,medicine.disease ,Prognosis ,Combined Modality Therapy ,Lymphoproliferative Disorders ,Lymphoma ,CD4 Lymphocyte Count ,Purines ,Immunology ,Rituximab ,Female ,business ,medicine.drug ,Stem Cell Transplantation - Abstract
The aims of this study were to evaluate the clinical characteristics of HIV-negative patients affected by lymphoproliferative disorders (LPD) who developed progressive multifocal leukoencephalopathy (PML), to delineate the risk factors, and to analyze whether the new antineoplastic therapies are changing the natural history of this infectious disease. We retrospectively analyzed 46 cases with confirmed LPD-associated PML published from 1958 to 2004. Patients were stratified according to two different time periods: group A included patients diagnosed before 1989, and group B included patients diagnosed since 1990, after introduction of purine analogues. Group A patients (n = 22) had received alkylating agents and/or radiotherapy, and the majority (63.6%) had advanced Hodgkin disease. At univariate analysis, uncontrolled Hodgkin disease was the only risk factor for PML. In group B patients (n = 24), the most frequent treatments received were purine analogues (58.3%) and high-dose therapy with hematopoietic stem cell transplantation (33.3%; HDT/HSCT). B-cell chronic lymphocytic leukemia (45.8%) and aggressive non-Hodgkin lymphoma (24.9%) were the most frequent underlying LPDs. Patients treated with purine analogues were more likely to have active LPD, lower CD4 cell counts, and to be older and male than were HSCT recipients. The median interval from purine analogues or HDT/HSCT to PML was 11 months. In HDT/HSCT recipients, this interval was delayed for 10 months when peri-transplantation rituximab was used. Univariate analysis identified age >55 years, male sex, and CD4 cell counts £0.2 · 10 9 /L as risk factors for PML in patients treated with purine analogues. Mortality rates were 95.4% (group A patients), 90% (purine analogues), and 62.5% (HDT/HSCT recipients). At univariate analysis, the only factor that significantly correlated with recovery from infection was female sex. Our findings indicate (1) the possible reduction in reported cases associated with Hodgkin disease and the increasing number of published cases associated with the new antineoplastic therapies (purine analogues and HDT/ HSCT); (2) among patients treated with purine analogues, PML is more common in male patients with CD4 cell counts £0.2 · 10 9 /L; (3) the use of rituximab after HDT/ HSCT seems to delay the onset of PML; and (4) the prognosis is slightly better in transplant recipients. Am. J. Hematol. 80:271‐281, 2005. a 2005 Wiley-Liss, Inc.
- Published
- 2005
33. Iatrogenesis or bad luck? relapse of an LMP1-positive follicular lymphoma after immunosuppression for hepatitis-associated aplastic anaemia
- Author
-
Montserrat López-Rubio, J. Garcia-Suarez, Isabel Krsnik, and Alicia Santana
- Subjects
Male ,medicine.medical_specialty ,Herpesvirus 4, Human ,Skin Neoplasms ,Hepatitis, Viral, Human ,medicine.medical_treatment ,Iatrogenic Disease ,Follicular lymphoma ,Gastroenterology ,Iatrogenesis ,Viral Matrix Proteins ,Fatal Outcome ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Aplastic anemia ,Lymphoma, Follicular ,Antilymphocyte Serum ,Hepatitis ,Immunosuppression Therapy ,business.industry ,Lamivudine ,Anemia, Aplastic ,Immunosuppression ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Immunology ,Cyclosporine ,Rituximab ,Virus Activation ,Complication ,business ,medicine.drug - Abstract
A 55-year-old man suffered a cutaneous relapse of an LMP1-positive follicular lymphoma after treatment with antithymocyte globulin and cyclosporine A (CSA) for a hepatitis-associated aplastic anaemia (AA). Rituximab was not effective, so CSA was tapered off. Lymphoma masses did not regress but AA relapsed. A second remission of both lymphoma and AA was achieved with high-dose cyclophosphamide, but the patient died of a bilateral pneumonia. The relationships between immunosuppression, viral reactivation and tumour growth are discussed. The use of rituximab and lamivudine in immunodepressed patients is also commented.
- Published
- 2002
34. Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM)
- Author
-
Norma C. Gutiérrez, Jose Francisco Tomas, Ma Jesús Blanchard, Isabel Krsnik, Ma Victoria Mateos, Juan José Lahuerta, Belén Iñigo, Jesús F. San Miguel, Laura Rosiñol, Miguel T. Hernandez, Luis Palomera, Ana Isabel Teruel, Javier de la Rubia, Raquel Jiménez-Segura, Dolores Hernández, and Joan Bladé
- Subjects
Cancer Research ,medicine.medical_specialty ,Intention-to-treat analysis ,business.industry ,Immunology ,Combination chemotherapy ,Cell Biology ,Hematology ,medicine.disease ,Gastroenterology ,Biochemistry ,Surgery ,Thalidomide ,Regimen ,Oncology ,Maintenance therapy ,Statistical significance ,Internal medicine ,Medicine ,business ,Multiple myeloma ,Progressive disease ,medicine.drug - Abstract
Introduction In April 2006, the Spanish Myeloma Group (PETHEMA/GEM) initiated a randomized phase III trial (GEM05menos65) comparing induction with thalidomide/dexamethasone (TD) vs. bortezomiv/thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Bortezomib (VBMCP/VBAD/B) in patients 65 years-old or younger with newly diagnosed symptomatic MM followed by ASCT with MEL-200 and maintenance therapy with interferon vs, thalidomide alone or bortezomib/thalidomide. The results of the overall series has been previously published. However, the efficacy of novel agents in patients with extramedullary disease is not well stablished. Primary end points to describe the characteristics and outcome of patients with EMPs homogeneously treated in the GEM05menos65 trial. Patients and Methods TD consisted of thalidomide 200 mg daily (escalating doses in the first cycle) and dexamethasone 40 mg on days 1-4 and 9-12 at 4-week intervals for 6 cycles. The VTD regimen was identical to TD plus i.v. bortezomib 1.3 mg/m2 on days 1,4,8,11 of each cycle. Combination chemotherapy plus bortezomib consisted of 4 cycles of VBMCP/VBAD on an alternating basis followed by 2 cycles of i.v. bortezomib (1.3 mg/m2 on days 1,4,8, and 11 every 3 weeks). The duration of the induction therapy was 24 weeks in all arms. From April 6, 2006 to August 5, 2009 the 390 planned patients entered the study. 66 patients (17%) had extramedullary plasmacytomas (median age: 54 years, M: 33, F: 33). The isotype was IgG: 41, IgA 11, Bence-Jones: 10, IgD:4; kappa:41, lambda: 25.The stage according to the ISS was I in 27 patients, II in 26 and III in 13 patients. The location of the EMPs was soft-tissue masses arising from lytic lesions in 60 patients, testicular mass with no contact with bone in 1 case and was not specified in 6 cases. Nine patients had multiple extraosseous plasmacytomas. 17 patients received induction therapy with VBMCP/VBAD/B, 23 with TD and 26 with VTD. Results Cytogenetic information was available in 51 out of the 66 cases with EMPs and 12 of them (23%) showed high-risk cytogenetics. There were no differences in the incidence of high-risk cytogenetics (t(4;14), t(14;16) and del 17p) in patients with and without EMPs (23% vs 21%). The incidence of t(4;14) in patients with and without EMP was 16% vs 23%, respectively. The incidence of del 17p was 10% and 6% in patients with and without EMPs.The IFE negative CR rate was significantly higher with VTD as compared to TD (42% vs 13%, p=0.02) while there was no significantly differences among VTD and VBMCP/VBAD/B (42% vs 29%, p=NS). Patients with EMP had a significantly higher rate of PD during induction therapy as compared to patients without EMPs (24% vs 11%, p=0.01). This higher rate of PD in patients with EMP was observed in the 3 induction arms (VBMCP/VBAD/B 24% vs 9%, TD 40% vs 19%, VTD 12% vs 6%). 43 patients received ASCT as part of the treatment design. On an intention to treat basis, the pos-ASCT CR rate was higher with VTD arm compared to TD (50% vs 22%, p=0.07) but not significantly different from VBMCP/VBAD/B (50% vs 41%, p=0.7). After a median follow-up of 46 months, there was no significant differences in PFS between patients with or without EMP (26.9 vs 39.9 months, p=0.47). Although the difference did not reach statistical significance, there was a trend towards a shorter PFS for patients with EMPs with high-risk cytogenetics (median 12.1 vs. 28.3 months, p=0.13). In patients with EMPS, the PFS was not reached in the VTD arm versus 26.9 months with VBMCP/VAB/B and 22.8 moths with TD. The OS was significantly shorter in patients with EMPs as compared to patients without EMPs (median 69.9 months vs not reached, p=0.02) Conclusion 1) In the present study the frequency of EMPs was 17%, 2) the incidence of high-risk cytogenetics in patients with EMPs was similar to that observed in patients with no extramedullary disease, 3) patients with EMPs had a higher rate of progressive disease irrespective of the induction arm as compared to patients without EMPs, being VTD the best treatment option, 4) finally, the OS was significantly shorter in patients with EMPs. Disclosures: Rosiñol: Janssen: Honoraria; Celgene: Honoraria. De La Rubia:Janssen: Honoraria; Celgene: Honoraria. Mateos:Jansen: Honoraria; Celgene: Honoraria. Tomas:MedImmune: Research Funding. Gutiérrez:Jansen: Honoraria; Celgene: Honoraria. San Miguel:Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Millenium: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Onyx: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. Lahuerta:Janssen: Honoraria; Celgene: Honoraria. Blade:Janssen: Honoraria; Celgene: Honoraria.
- Published
- 2013
35. Paroxysmal Nocturnal Hemoglobinuria and Magnetic Resonance Imaging
- Author
-
José Luis Bueno, José A. García-Marco, Martin Cabero, Isabel Krsnik, Emilio Ojeda, Santiago Gil, Almudena de Laiglesia, Carmen Regidor, Daniel Morillo, Rafael Fores, Beatriz Brea, Belen Navarro, Miguel Pastrana, Jose Rafael Cabrera, Cristina Muñoz-Linares, and Guiomar Bautista
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Immunology ,Bone marrow failure ,Magnetic resonance imaging ,Cell Biology ,Hematology ,Eculizumab ,medicine.disease ,Biochemistry ,Thrombosis ,Surgery ,Atheromatosis ,medicine.anatomical_structure ,medicine ,Paroxysmal nocturnal hemoglobinuria ,Abdomen ,Radiology ,business ,Rare disease ,medicine.drug - Abstract
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and complex disease characterized by a severe prothrombotic state caused by a complement system mediated hemolysis. The introduction of the anti-C5 antibody, Eculizumab, has been conducted in many Hematology units worldwide to adopt new diagnostic tools to evaluate new and old PNH patients in order to consider the adequacy of the adoption of this new drug in each case. Magnetic Resonance Imaging (MRI) allows a more adequate and profitable approach in PNH that other radiology techniques used for this purpose. In the last four years Hematology and Radiology units in our Hospital have collaborate in the clinical evaluation of PNH patients performing MRI (cranioencephalic, thoracic and/or abdominal) in acute complications of PNH patients (9 patients) or as a programmed protocoled evaluation previous to consider Eculizumab treatment (14 patients). The protocoled evaluation consists in thoracic and abdominal MRI evaluations in all cases, and cranioencephalic MRI (with independence of the presence of neurological symptoms) in 9 cases. The PNH patients were examined with 1.5 Teslas magnet for cranioencephalic,thoracic and abdominal MRI and with 3.0 Teslas magnet for some cranioencephalic MRI (Achieva Magnets; Philips Healthcare, Best, The Netherlands). Different protocols designed for the study of this pathology, using morphological sequences with different empowerment, functional sequences and angiographic studies after administration of intravenous contrast (gadobutrol) have been used. In the abdominal explorations had been performed calculations of T2 * for the quantification of deposit of iron in liver and kidney. The first group of patients (incidental studies in acute/chronic situations) included Classical and with other bone marrow failure syndrome (BMFS) Parker’s types. The second group (protocoled studies previous consideration of Eculizumab therapy) consisted on 11 Classical Parker’s type patients with active hemolysis (LDH increased 3-13 times over normal levels) and elevated PNH clone (73-99% negative GPI granulocytes by FLAER cytometry); and 3 with BMFS Parker’s type patients (LDH increased 2-6 times over normal levels) with lower PNH clone (43-50% negative GPI granulocytes by FLAER cytometry). Thrombosis was found in four cases, one in the inferior cava and and three arterial (two cerebral and one in descendent aorta). In three patients this finding implied to initiate Eculizumab therapy. Minor ischemic brain changes were displayed by three patients. None of the eighteen patients explored with thoracic MRI, displayed pulmonary hypertension signs despite the elevation of pro-BNP in eight of them. Iron overload in the liver and/or kidneys were very frequent. The finding of a reversal of the normal cortical and medullary intensities on T1 and T2 weighted images of both kidneys was evident in the majority of patients with severe PNH types. Interestingly, one patient with a chronic PNH severe form displayed no renal iron cortical after two years on Eculizumab therapy. This finding was also evident in patients with active hemolysis in the past but with very low PNH clones and clinical remission of the disease. Many other incidental discoveries includes cholelithiasis, splenomegaly, kidney arterial vessel constriction, vascular anomalies, kidney and vesical stones, adrenal adenoma, atheromatosis at different levels, Tornwaldt cyst, hamartoma, hemangiomas and abnormal bone marrow signal. MRI is the best imaging technique to diagnose thrombosis in PNH patients and to control evolution. Moreover, in the cerebrovascular setting allows a more fine and precise diagnosis of the minor pathologic thrombotic changes. MRI is the only imaging technique that permits to evaluate the iron overload that in some PNH cases could be underestimated and needs quelation therapy. In our opinion all new patients with classical severe hemolytic PNH must be evaluated prospectively with MRI. The collaboration of the Radiology team with the Hematologist is fundamental to acquire expertise in this rare disease. Disclosures: Pastrana: Alexion Pharmaceuticals: Speakers Bureau. Ojeda:Alexion Pharmaceuticals: Consultancy, Speakers Bureau.
- Published
- 2013
36. Paroxysmal Nocturnal Hemoglobinuria and Thrombosis Before and After Eculizumab
- Author
-
Belen Navarro, Santiago Gil, Daniel Morillo, Almudena de Laiglesia, José Luis Bueno, Carmen Regidor, Jose Rafael Cabrera, José A. García-Marco, Rafael Fores, Guiomar Bautista, Miguel Pastrana, Cristina Muñoz-Linares, Isabel Krsnik, Martin Cabero, and Emilio Ojeda
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Bone marrow failure ,Warfarin ,Atrial fibrillation ,Cell Biology ,Hematology ,Eculizumab ,medicine.disease ,Biochemistry ,Thrombosis ,Pancytopenia ,Surgery ,medicine.anatomical_structure ,medicine ,Paroxysmal nocturnal hemoglobinuria ,Vein ,business ,medicine.drug - Abstract
Thrombosis, mainly venous but also arterial, is the leading threat in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients, caused by the continuous hemolysis. It constitutes the first cause of death in all reported series. Since 1964, a total of 56 patients with PNH clone were evaluated in our Hematology Unit. According with PNH Parker´s Classification, most of the patients were Classical type (28 patients), and the remaining included in the other subsets: 21 in the setting of another bone marrow failure syndrome (BMFS) and 7 subclinical. Since November 2007, Eculizumab (an anti-C5 antibody) is employed in the disease to abrogate the hemolysis in our patients. In the last years, sixteen patients have been treated with this drug in our series. PNH patients previously anticoagulated with warfarin because thrombosis, continued on therapy after the addition of Eculizumab. Also, patients with more than 50 % PNH clone (established by Cytometry with FLAER on granulocytes) and platelets >50 x109/L received oral anticoagulation. The incidence and localization of thrombotic events in the patients without Eculizumab was as follows:Parker’s ClassificationClassicalBMFSSubclinical28216Thrombosis cases (%)14 (50)4 (20)2 (33)Thrombotic episodes:2675Deep calf642Multiple cerebral ischemic infarcts212 (1 death)Large Cerebrovascular311Budd-Chiari11 (1 death)Portal2 (1 death)Retinal2Cava1Pulmonary thromboembolism2 (1 death)Myocardial infarction3 (1 death)Arterial ischemia2 (1 amputation)Skin ischemic2 (vasculitis, livedo reticularis) After introduction of Eculizumab, sixteen patients have been treated with this drug and active thrombosis resolved in all cases, as was the case of a patient with a large persistent thrombosis in the inferior cava vein despite the isolated anticoagulation therapy. Only one patient on Eculizumab therapy experienced a thrombotic event and suffered a transient ischemic attack with aphasia after a prolonged catheter ablation procedure for an atrial fibrillation. This patient had previous signs of small vessel disease in MR imaging techniques. The episode occurs despite heparin anticoagulation and anticipated additional Eculizumab dose and resolves thereafter. Eculizumab had a clear favourable impact in preventing thrombosis complications in our series of PNH patients. Careful monitoring of LDH levels and shortening the Eculizumab interval doses it is indicated in any chirurgical or invasive procedures in these patients. Disclosures: Pastrana: Alexion Pharmaceuticals: Speakers Bureau. Ojeda:Alexion Pharmaceuticals: Consultancy, Speakers Bureau.
- Published
- 2013
37. Paroxysmal Nocturnal Hemoglobinuria and Cancer: High Incidence Of Cancer In a Large Series Of PNH Patients In a Single Center
- Author
-
Belen Navarro, Martin Cabero, Rafael Fores, Emilio Ojeda, José Luis Bueno, Daniel Morillo, Santiago Gil, José A. García-Marco, Almudena de Laiglesia, Guiomar Bautista, Carmen Regidor, Cristina Muñoz-Linares, Isabel Krsnik, and Jose Rafael Cabrera
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Immunology ,Bone marrow failure ,Cancer ,Immunosuppression ,Cell Biology ,Hematology ,Eculizumab ,Liver transplantation ,medicine.disease ,Biochemistry ,Gastroenterology ,Surgery ,Transplantation ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Paroxysmal nocturnal hemoglobinuria ,Aplastic anemia ,business ,medicine.drug - Abstract
Since 1964, a total of 56 patients with Paroxysmal Nocturnal Hemoglobinuria clone (PNH) were evaluated in our Hematology Unit. The PNH was evaluated with Ham’s and/or sucrose tests until 1993, when the firsts cytometric analysis of PNH were performed in our Laboratory with CD55 and CD59 markers on granulocytes mainly, and since 2011 also with the FLAER technique. According with PNH Parker´s Classification, most of the patients were Classical PNH type (28 patients), and the remaining included in the other subsets such as 21 PNH in the setting of another bone marrow failure syndrome (BMFS) and 7 PNH subclinical. Most of the patients (70%) displayed an Aplastic Anemia (AA) before or concomitantly with the diagnosis of PNH, and received immunosuppressant drugs (Steroids with/out antithymocyte globulin & Cyclosporine). In four patients an Allogeneic Hematopoietic Transplantation was performed due to a Severe Aplastic Anemia (2 patients), a Classical Severe PNH (before Eculizumab era) or a Myelodysplastic Syndrome. Another patient received a Liver Transplantation because of advanced Hepatitis C related liver failure. In our PNH series, an unexpected high incidence of cancer has appeared, with 8 patients (14,5%) displaying different hematological or non-hematological cancers in the lasts years:SexAge Diagnosis PNHParker’s ClassificationYear Diagnosis PNHYear Diagnosis CancerPrevious ImmunosuppressionCancerYear Death♂16Classical19692011YesLymphoma2011AA & Liver Tx♀30Classical19732003NonePancreatic2006♂38Classical19741995NoneGastric20122012Pulmonary♂26Classical19892013Yes, SteroidsCerebralAlive♀25Classical19942005YesLymphoma2006AA & Cord-Blood Tx♂40BMFS19951995Yes, SteroidsLiver1995♂75BMFS20112009NoneSeminoma2012*♂56Subclinical20101999Yes, SteroidsProstaticAlive*Dead because bone marrow failure. In our PNH series, cancer reports as one of the most frequent final cause of death, with thrombosis with similar incidence (11 patients of the 56 are dead, with 5 patients dead because thrombosis), although the high incidence and severity of thrombosis episodes in this cohort of patients (20 patients experienced thrombosis with a total of 40 events). As displayed supra, some of the cancers could be attributed to the therapy applied in particular patients: The two secondary lymphomas after organ transplantation could be explained by the immunosuppression employed in these procedures. Only three patients did not received immunosuppressant drugs before cancer diagnosis. This high mortality cancer rate precludes the indiscriminate use of steroids in PNH patients. This result, never reported before in PNH, merits an investigational survey of cancer incidence in PNH patients in the PNH International Registry. Disclosures: Ojeda: Alexion Pharmaceuticals: Consultancy, Speakers Bureau.
- Published
- 2013
38. Chagas disease in a recipient of cord blood transplantation
- Author
-
José A. García-Marco, Guiomar Bautista, Elena Ruiz, Carlos Vallejo, Isabel Krsnik, M Linares, Rafael Fores, Carmen Regidor, R López-Vélez, J R Cabrera, Emilio Ojeda, Santiago Gil, F Portero, Sanjuán I, and M N Fernández
- Subjects
Chagas disease ,Transplantation ,Pediatrics ,medicine.medical_specialty ,Blood transfusion ,biology ,business.industry ,medicine.medical_treatment ,Public health ,Hematology ,Disease ,biology.organism_classification ,medicine.disease ,Organ transplantation ,parasitic diseases ,Immunology ,medicine ,Congenital transmission ,Trypanosoma cruzi ,business ,Cord blood transplantation - Abstract
American trypanosomiasis, or Chagas' disease, is caused by a protozoan, Trypanosoma cruzi. It is endemic in Latin America where it represents a major public health problem. Chagas' disease also occurs in non-endemic areas where it can be acquired by blood transfusion, congenital transmission and organ transplantation. The disease can be fatal in immunosuppressed patients.1 We report a case of reactivation of Chagas' disease (acute form) in a patient who underwent cord blood transplantation in a non-endemic European country.
- Published
- 2007
39. Use of Romiplostim to Facilitate Platelet Engraftment in Allogeneic Hematopoietic Transplantation
- Author
-
Emilio Ojeda, Santiago Gil, Almudena DelaIglesia, Sanjuán I, Amelia Sanchez-Guerrero, Belen Navarro, Gracia Bravo, Rosa Gonzalo-Daganzo, Martin Cabero, Carmen Regidor, Pilar Beltran, Jose Rafael Cabrera, Trinidad Martín-Donaire, Rocio Sanchez, Rafael Fores, José A. García-Marco, Guiomar Bautista, Isabel Krsnik, and Nuria Claros
- Subjects
Thrombopoietin receptor ,medicine.medical_specialty ,Romiplostim ,Platelet Engraftment ,business.industry ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Platelet transfusion refractoriness ,Transplantation ,Platelet transfusion ,Internal medicine ,Anesthesia ,medicine ,Platelet ,business ,medicine.drug ,Hemorrhagic cystitis - Abstract
Abstract 1947 Background: Thrombocytopenia requiring platelet transfusions is a constant in the hematopoietic transplantation (HT). In some situations, like the adult non-related donor and cord blood HT, the platelet engraftment is delayed for a long time. Hemorrhagic cystitis, venooclusive disease, graft-vs-host disease could to worse these procedures with a very high risk of bleeding and to increase the transplantation morbi-mortality. The agonists of thrombopoietin receptor (TRAs) have demonstrated to increase the platelet production in different pathological situations, like in the ITP and MDS patients. Thus, these new drugs could have a potential benefit in other clinical situations with low platelet production. Methods: We describe our experience in seven patients with Allogeneic HT using Romiplostim (NPlate®, Amgen Inc.), a parenteral TRA peptide, to accelerate the platelet engraftment or to increase the platelet level in the thrombocytopenia induced by HT conditioning or HT related complications. We have administrated Romiplostim in a compassionate basis (off-label). In all cases the drug was administered subcutaneously at a dose of 250 mcg. Most of the patients received only one dose, with the exception of patients #1 and 7, whom received two doses separated by seven days. The first case, a woman diagnosed as Acute Lymphoblastic Leukemia (ALL) with severe HLA platelet refractoriness acquired in the induction and consolidation chemotherapy treatments previous to HT, received two doses of 250 mcg of Romiplostim on days +4 and +12 after peripheral blood progenitor cells infusion from an HLA matched brother. Results: In the first case, a rapid and sustained platelet level increase was obtained, without platelet transfusional support. Encouraged by this successful result, we have used Romiplostim in six more patients with platelet refractoriness to platelet transfusions with or without bleeding. In all the patients the spleen was present. The patient #6, obtained a previous platelet engraftment that was loosed with the beginning of severe cGVHD. (see table) Conclusion: The use of Romiplostim could be very useful in HT complicated by severe platelet transfusions refractoriness. Our data encourages the realization of a randomized prospective study with this drug in HT. Graphic evolution of platelet count over time is depicted in the next figure: Days after Romiplostim administration. Number of platelets x109/L. Disclosures: Ojeda: Amgen Inc.: Consultancy, Honoraria. Off Label Use: Romiplostim (Nplate)is an agonist of thrombopoietin receptor (TRAs) that have demonstrated to increase the platelet production in different pathological situations, like in the ITP and MDS patients.
- Published
- 2011
40. Analysis of Procoagulants Phospholipids in Plasma of Paroxysmal Nocturnal Hemoglobinuria Patients,Processed in Differents Preanalytic Conditions
- Author
-
Isabel Krsnik, Beatriz Azcoitia, Carmen Regidor, Jose Rafael Cabrera, Martin Cabero, Isabel San Juan, Rafael Fores, Mirian Santero, Isabel Millán, Emilio Ojeda, Belen Navarro, Santiago Gil, Daniel Morillo, Almudena de Laiglesia, Pilar Beltran, Nuria Claros, Cristina Muñoz, Miguel A. Piris, Guiomar Bautista, José A. García-Marco, Rosa Gonzalo, and Trinidad Martin
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,Eculizumab ,medicine.disease ,Biochemistry ,Gastroenterology ,Pathophysiology ,Coagulative necrosis ,Internal medicine ,Fibrinolysis ,medicine ,Paroxysmal nocturnal hemoglobinuria ,Platelet ,Platelet activation ,business ,Complication ,medicine.drug - Abstract
Abstract 5258 Background: Paroxysmal Nocturnal Hemoglobinuria (PNH) is an infrequent hematopoietic stem cell disorder characterized by a higher risk of Tromboembolic disease. This complication is associated with hemolysis, Fibrinolysis and platelet activation. The increase in plasma of procoagulants microparticles from platelets has been incriminated in the pathophysiology of this complication. Up to now the analysis of microparticles has been made by Cytometry, ELISA, Electronic Microscope and thrombin generation, all of them very time-consuming and expensive techniques. Recently, an automatic quantification of microparticles has been introduced for procoagulant phospholipids time coagulation measurement. The objective of this study is to compare the procoagulant phospholipids levels in PNH and Aplasia/PNH overlap disease patients compared with twenty healthy subjects, in samples processed by different preanalytic conditions. Patients and Methods: After an informed consent, twenty healthy subjects (blood donors) matched for age and sex were selected as controls. Eighteen patients (15 PNH and 3 AA /PNH) followed in our Reference Unit. From these, 15 were men and 3 women. Median age of 45,5 yrs. (16–68), 12 were treated with different types of treatments (five of them with Eculizumab) and 6 were not treated. To measure microparticles, after double centrifugation 2500 g × 15 min, and separation in three aliquots, were stored at −80°C and −40°C, and a third sample was processed in fresh. A FXa based coagulative technique was used. Results: The media in controls was 86,3±11,0 seg in fresh, 78,3±13,5 seg at −40°C and 79,3±12,3 seg at −80°C. These differences were significant between the fresh samples at −40°C (p Conclusions: Through this automated coagulative technique based of FXa, a significant increased of microparticles has been observed in controls, at – 40°C and in less significance at −80°C respect fresh samples. In not treatment PNH patients a no significant microparticles levels increased has been measured (because of the reduced sample size) about controls. These differences disappear in treatment PNH patients. There is an increased in microparticles levels in PNH patients before treatment, that becomes normal in treatment patients. Moreover the freezing show an increasing of the plasma procoagulant activity higher at −40°C about −80°C. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2011
41. Translocation t(4; 6)(q21; q27) in a case of primary thrombocythaemia in transformation
- Author
-
J. García Suárez, Teresa Ferro, Y. Vázquez Mazariego, Isabel Krsnik, and P. Cabello
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Pathology ,medicine.medical_specialty ,Blast transformation ,Cytogenetics ,Chromosomal translocation ,Hematology ,Biology ,Primary thrombocythaemia ,Hydroxycarbamide ,Transformation (genetics) ,hemic and lymphatic diseases ,medicine ,Hidroxicarbamida ,medicine.drug - Abstract
We report a case of primary thrombocythaemia showing a translocation t(4; 6)(q21; q27) five years after diagnosis. The patient had been treated with hydroxyurea. The clinical picture at the time was consistent with transformation. Karyotypic abnormalities are rare in this disease and are reviewed.
- Published
- 2001
42. MYELOFIBROSIS IN PRIMARY MYELODYSPLASTIC SYNDROMES
- Author
-
Villegas A, E. Del Potro, Isabel Krsnik, A. Gonzalez Fernandez, Rafael Martínez, and M. Lopez Rubio
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Myelodysplastic syndromes ,Internal medicine ,medicine ,Hematology ,Myelofibrosis ,medicine.disease ,business - Published
- 2008
43. Use of Third Party Ancillary Cells for Enhancement of Full Donor Chimerism and Immunomodulation in Cord Blood Transplants
- Author
-
Santiago Gil, José A. García-Marco, Elena Ruiz, Sanjuán I, Manuel N. Fernandez, Rosa Gonzalo, Rafael Fores, Guiomar Bautista, Isabel Millán, Emilio Ojeda, Isabel Krsnik, Jose Rafael Cabrera, Carmen Regidor, and Belen Navarro
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Cell Biology ,Hematology ,Human leukocyte antigen ,Neutropenia ,medicine.disease ,Biochemistry ,Gastroenterology ,HLA Mismatch ,Haematopoiesis ,Median follow-up ,Internal medicine ,Cord blood ,Medicine ,Stem cell ,business ,Adverse effect - Abstract
We have pioneered co-infusion of a low number of T-cell highly depleted mobilized hematopoietic stem cells (MHSC) from a third party donor (TPD) as a tool to increase rates of cord blood transplant (CBT) engraftment and full chimerism in adults with high risk hematologic malignancies (“dual transplant”, Haematologica2006; 9:640–8). The conditioning regimes used have been myeloablative although of reduced extra-hematological toxicity. After achieving very favourable results regarding both engraftment and full chimerism, we have started using this approach to evaluate the addition of other TPD cells to the purpose of optimizing CBT immune reconstitution. Results on CBT engraftment, chimerism and survival are available for analysis at this time on 53 patients (M/F 33/20, median age 35 years, range 16–60) who received units with a total cell count (TCC) of 1.1 to 4.3 x 107/Kg (median 2.3) and 0–3/6 HLA disparities, who have received TPD MHSC: 38 from an haploidentical donor, 15 from a related or unrelated donor not sharing an HLA haplotype. Days to ANC>500/uL ranged 9–36 (P50: 11; P90: 20). Initially most of the ANC was predominantly from the TPD with increasing proportions of granulocytes of CB source. Days to full CB chimerisms ranged from 11 to 97 (P50: 37; P90: 93). With a median follow up of 15 months, 3 year OS and DFS of these 53 patients are 60% and 53%. OS for patients older and younger than 40 years are 50% and 64% respectively (p= 0,37). Five patients relapsed, 2 of them achieved new complete remission maintaining full CB chimerism. Acute GVHD occurred in 19 patients, most of them grade I-II with favorable response to treatment. Four cases were grade III-IV, causing death to 3 patients. Other were toxic (VOD 2, MOF 3 and cerebral hemorrhage 1) or infections (all but one CMV). These have been the main cause of morbidity after post-transplant neutropenia and were favoured by a slow recovery of the protective immunity. Reconstitution of lymphocyte subpopulations (detailed data available for 31) is similar to what has been described for single unit CBT: prompt recovery of NK cells (1 month), followed by recovery of B cells (3 months) and slower recovery of T cells subpopulations: T8 in about one year, T4 and T-regs within the second year. No adverse effects due to the co-infusion of the TPD MHSC have been observed. Ex-vivo expanded MSC from the same TPD have been co-infused to 8 patients in addition to the MHSC. The number of co-infused MSC has ranged 1.16–3.24 x 106 cells/kg (median 1.38) without adverse effects observed so far: ANC has occurred as in the other patients and only one had signs of aGVHD, who did nor achieve stable response to antivirals for CMV, achieving continued control of both after the infusion of a new dose of 1.12 x106 cells/kg. Conclusion: These results consolidate our previous description of the “dual transplant” strategy as an approach that may allow high rates of engraftment, full chimerisms and survival of HLA mismatch CBT of relatively low cell content for adults of a wide age range with haematological malignancies, with the possibility of adding other subpopulations of the same TPD as cell therapy tools.
- Published
- 2007
44. Single Unit Cord Blood Transplant Supported by Third Party Highly Purified Mobilized Hematopoietic Stem Cells: Immune Reconstitution Studies
- Author
-
Elena Magro, Adria Prieto, Elena Ruiz, Rosa Gonzalo-Daganzo, Guiomar Bautista, PJ Travers, N. Panadero, Isabel Millán, Rafael Fores, Alejandro Madrigal, Carlos Vallejo, José A. García-Marco, Emilio Ojeda, Rocio Sanchez, Carmen Regidor, Trinidad Martín-Donaire, Manuel N. Fernandez, Sanjuán I, Rafael Cabrera, and Isabel Krsnik
- Subjects
T cell ,Immunology ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Andrology ,Transplantation ,Haematopoiesis ,Immune system ,medicine.anatomical_structure ,Immunophenotyping ,Cord blood ,medicine ,Cytotoxic T cell ,CD8 - Abstract
Background and Objectives: Following cord blood transplants (CBT) there is a period of severe and often prolonged immune deficiency that results in long term susceptibility to infections. Immune reconstitution is an important factor for long term survival. We analyzed the immune reconstitution of adult recipients of a single unit CBTs supported by a low number of third party donor highly purified mobilized hematopoietic stem cells (dual CB/TPD transplants), as previously described (Magro et al. Haematologica2006;91:640–8). This strategy results in transient double chimerism of CB and TPD cells and early granulocyte recovery, initially of TPD predominance. Complete CB chimerism is regularly achieved within 100 days.The objective of this study is to evaluate immune reconstitution in this CBT. Patients and Methods: Data were obtained from 19 patients between July 2004 and July 2006. Data collection was initiated at different intervals (from day −7 to +720, quartiles Q1=35, Q2=90 and Q3=210). Samples were obtained on days +15, +35, +55, +90 and monthly thereafter up to two years. By four-color flow cytometric immunophenotyping we analyzed the subsets of peripheral blood lymphocytes: CD3+/CD4+ (T helper/inducer), CD3+/CD8+ (T suppressor/cytotoxic), NK cells (CD3−/CD56+/CD16+) and B cells, as well as cells with naïve, memory and effector T-cell immunophenotypes. TREC bearing cells were analyzed by quantitative PCR in sorted CD4+ and CD8+ T cells collected from 3 months post-transplant onwards. Results: CD56+ cells recovered early after transplantation, with median absolute number counts (ANC) of 69 (range 18–307), 170 (0–366) and 159 (32–531) cells/uL in days +15, +35 and +55 samples [normal controls 153 (71–438)], representing the largest subset within the first two months (decreasing proportions of 60%, 50% and 40%, respectively). ANC of CD4 and CD8 T cells remained low for several months, progressively increasing to reach normal ranges at different intervals. Naïve CD4 and CD8 cells (CD45RO−/CD27+) start to be detected by immunophenotyping after three months post-transplantation with median ANC of 17 (12–79) and 12 (5–103) cells/uL respectively and increasing thereafter [normal controls 860 (552–1072) and 331 (227–521)]. By the end of the first year values of T cell subsets were: CD4+, 823 (16–1123) cells/uL [normal controls 872 (470–1093)]; CD8 934 (56–1174) [normal controls 371 (208–808)], with persisting predominance of the naive phenotypes and proportions of memory phenotypes slowly increasing. B cells became detectable around day +90 with median ANC of 249 (0–1934) cells/uL, rapidly reaching values within the normal range [275 (133–684)]. Transient acute GVHD was developed by six of the 19 patients. All showed a transient drop in absolute numbers of NK, T and B cells. Chimerism analysis showed initial transient double chimerism of CB and TPD cells. Complete CB chimerism was achieved between days +15 and +94 (median, +35). Results of chimerism of lymphocyte subsets and TREC are not yet available. Conclusions: Following dual CB/TPD transplants we have observed early recovery of NK and B-cells and slow development of T cells subsets and of non-naive immunophenotypes.
- Published
- 2006
45. Cord blood transplantation supported by co-infusion of CD133-positive hematopoietic stem cells from a third party donor: Preliminary results
- Author
-
Rafael Cabrera, Isabel Krsnik, Rafael Fores, Carmen Regidor, José A. García-Marco, Isabel Millán, and M.N. Fernández
- Subjects
Oncology ,Transplantation ,medicine.medical_specialty ,Haematopoiesis ,Third party ,business.industry ,Internal medicine ,medicine ,Hematology ,Stem cell ,business ,Cord blood transplantation - Published
- 2006
46. Peripheral Thrombocytopenia, Accessory Spleen and Hodgkin’s Disease: An Unusual Combination
- Author
-
M. A. Calero, G Pérez-Rus, Isabel Krsnik, J. Garcia-Suarez, M. P. Ricard, and F. Perera
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,Splenectomy ,Spleen ,Accessory spleen ,Scintigraphy ,Autoimmune thrombocytopenia ,Autoimmune Diseases ,Immunopathology ,medicine ,Humans ,Radionuclide Imaging ,medicine.diagnostic_test ,business.industry ,Remission Induction ,Technetium ,Immunosuppression ,Hematology ,General Medicine ,medicine.disease ,Combined Modality Therapy ,Hodgkin Disease ,Thrombocytopenia ,Lymphoma ,medicine.anatomical_structure ,Tomography, X-Ray Computed ,business ,Splenosis - Abstract
A 32-year-old male developed severe autoimmune thrombocytopenia refractory to conventional immunosuppression. He had been treated with radiotherapy for stage I-A Hodgkin's disease (HD) 2 years earlier after a staging laparotomy and splenectomy. A 3-cm accessory spleen was detected using computed tomography scan and 99mTc scintigraphy. Resection resulted in normalization of the platelet counts. Two years later the patient remains in remission of both diseases. Immune thrombocytopenia is rarely associated with HD and its remission following resection of an accessory spleen is an unusual finding.
- Published
- 1994
47. Letter to the editor: EDTA-dependent pseudothrombocytopenia in ambulatory patients: Clinical characteristics and role of new automated cell-counting in its detection
- Author
-
J L Merino, J. García Suárez, M. P. Ricard, F. Perera, Isabel Krsnik, M. A. Calero, and G P Rus
- Subjects
Pediatrics ,medicine.medical_specialty ,Letter to the editor ,business.industry ,Pseudothrombocytopenia ,Ambulatory ,MEDLINE ,Medicine ,Hematology ,Cell counting ,business - Published
- 1992
48. Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia
- Author
-
M. A. Calero, J. Garcia-Suarez, M. López‐Rubio, J. F. Del Campo, Isabel Krsnik, and K. Arribalzaga
- Subjects
medicine.medical_specialty ,medicine.anatomical_structure ,business.industry ,Internal medicine ,medicine ,Hematology ,Ticlopidine ,Granulocyte ,business ,Severe Aplastic Anemia ,medicine.drug ,Granulocyte colony-stimulating factor ,Surgery - Published
- 1995
49. SYSTEMIC MASTOCYTOSIS AND PRIMARY THROMBOCYTHAEMIA
- Author
-
M. A. Calero, G. Perez Rus, Juana Merino, L. M. Escribano, M. P. Ricard, F. Perera, J. García Suárez, and Isabel Krsnik
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,Hematology ,Systemic mastocytosis ,business ,medicine.disease ,Dermatology ,Primary thrombocythaemia - Published
- 1991
50. Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial
- Author
-
Luis Palomera, Juan Flores-Montero, María-Belén Vidriales, María José Calasanz, Josep Sarrá, Lourdes Cordón, Noemi Puig, Maria-Victoria Mateos, Maria Luisa Martin-Ramos, Jesús F. San Miguel, Laura Rosiñol, M Jesús Blanchard, Lucia Lopez-Anglada, Miguel T. Hernandez, Juan José Lahuerta, Norma C. Gutiérrez, Rafael Martínez, Jesús Martín, Joan Bladé, Albert Oriol, Javier de la Rubia, María Teresa Cedena, Ramón García-Sanz, Isabel Krsnik, J. Bargay, Bruno Paiva, Leire Burgos, José M. Moraleda, Joaquin Martinez-Lopez, Rafael Rios, and Alberto Orfao
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Treatment outcome ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Minimal residual disease ,Treatment efficacy ,Recurrence risk ,Clinical trial ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Family medicine ,medicine ,Relapse risk ,business ,Multiple myeloma ,030215 immunology - Abstract
Background: MRD is an established biomarker to evaluate treatment efficacy, define patients at risk based on persistent MRD, and eventually, act as surrogate for prolonged survival based on sensitive MRD-negative definitions. Accordingly, the IMWG has developed criteria for MRD-negativity defined by next-generation sequencing, NGF or PET/CT, and has recommended their inclusion in clinical trials. Notwithstanding, most flow cytometry results have been obtained using less sensitive methods and in fact, there is no data about the impact of NGF-based MRD assessment in clinical trials. Aim: To define the feasibility, sensitivity and clinical impact of NGF-based MRD assessment in the phase III PETHEMA/GEM2012 trial. Methods: A total of 458 patients were enrolled into the PETHEMA/GEM2012 trial. MRD was predefined to be prospectively assessed at three time-points: after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), after HDT/ASCT, and after two courses of consolidation with VRD. MRD monitoring was performed blinded for clinical outcomes in four PETHEMA/GEM laboratory cores, and data was centralized for MRD analyses. MRD assessment was performed following EuroFlow SOPs in a total of 1,134 bone marrow (BM) samples from 419 patients. The 39 cases without MRD assessment had suboptimal response to induction and were thus considered as MRD+ for intention-to-treat analyses. Noteworthy, in 14 BM samples with undetectable MRD, B-cell precursors, erythroblasts and mast cells represented Results: Overall, 225/458 (49%) patients had undetectable MRD at the latest time-point in which MRD was assessed and were thus classified as MRD-. Conversely, 233/458 (51%) cases remained MRD+: 28% with ≥10-4 MRD, 12% with 10-5 MRD, and 11% with 10-6 MRD. Detailed analyses of MRD kinetics in 320 patients with available MRD results at all three time-points, showed that the percentage of MRD- patients increased from 35% into 54% and 58% after induction, HDT/ASCT and consolidation, respectively. Furthermore, a restricted analysis among MRD+ patients showed that whereas after induction only 8% of them had MRD levels as low as 10-6, subsequent intensification with HDT/ASCT and consolidation could reduce MRD levels down to 10-6 in 32% of MRD+ cases. Progression-free survival (PFS) rates at 3-years were of 92%, 70%, 54% and 44% for patients being MRD-negative, MRD+ 10-6, 10-5 and ≥10-4, respectively (P Conclusions: This is the largest study of MRD monitoring in MM based on the total number of samples analyzed (n=1,134). Our results show that NGF-based MRD assessment is feasible in large multicenter clinical trials, is highly-sensitive, and allows the identification of hemodiluted BM samples inadequate for MRD assessment. Risk of relapse among MRD-negative patients was remarkably reduced (3%), and was particularly related to the reappearance of extramedullary plasmacytomas, which urges the need for combined cellular and imaging MRD monitoring in these patients; by contrast, even MRD levels as low as 10-5 and 10-6 conferred significantly inferior PFS. Overall, this study defines MRD-negativity as the most relevant clinical endpoint for both standard- and high-risk transplant-eligible MM patients. Figure Figure. Disclosures Paiva: Sanofi: Consultancy, Honoraria, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria; Merck: Honoraria; Novartis: Honoraria; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; EngMab: Research Funding. Oriol: Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: sponsored symposia, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: sponsored symposia, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: sponsored symposia; Celgene: Speakers Bureau. de la Rubia: Janssen: Other: Honoraria; Amgen: Other: Honoraria; Celgene: Other: Honoraria. Rosinol: Celgene: Honoraria; Janssen: Honoraria. Mateos: Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Lahuerta: Amgen: Honoraria; Celgene: Honoraria; Janssen: Honoraria. San Miguel: Roche: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees; MSD: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.